var title_f30_62_31712="Pectus excavat photo";
var content_f30_62_31712=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pectus excavatum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pectus excavtum in an adolescent patient demonstrating severe invagination of the lower sternum. The patient had significant exercise intolerance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Chung EK. Visual Diagnosis in Pediatrics. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_62_31712=[""].join("\n");
var outline_f30_62_31712=null;
var title_f30_62_31713="Antiphospholipid antibody syndrome - purpura";
var content_f30_62_31713=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Purpura in antiphospholipid antibody syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retiform purpura are present on the buttock.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_62_31713=[""].join("\n");
var outline_f30_62_31713=null;
var title_f30_62_31714="Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)";
var content_f30_62_31714=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/21/16723\">",
"         Patient information: C-section (cesarean delivery) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/43/692\">",
"         Patient information: Type 1 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/44/33475\">",
"         Patient information: Type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/58/28579\">",
"         Patient information: Using insulin (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/45/11988\">",
"         Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/45/10966\">",
"         Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/31/35317\">",
"         Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/43/39603\">",
"         Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/care-during-pregnancy-for-women-with-type-1-or-type-2-diabetes-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1479066212\">",
"      <span class=\"h1\">",
"       Can women with type 1 or type 2 diabetes have a healthy pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most women with type 1 or type 2 diabetes (sometimes called &ldquo;diabetes mellitus&rdquo;) can have a healthy pregnancy. But it&rsquo;s important for women with diabetes to get their blood sugar levels under control. Women whose blood sugar levels are under control are less likely to have problems during pregnancy. Women with high blood sugar levels are more likely to have problems during pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1479066219\">",
"      <span class=\"h1\">",
"       What problems can be caused by high blood sugar levels?",
"      </span>",
"      &nbsp;&mdash;&nbsp;High blood sugar levels can cause problems throughout pregnancy:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Early on, high blood sugar levels can increase the chance that a woman has a miscarriage. A miscarriage is when a pregnancy ends on its own.",
"       </li>",
"       <li>",
"        High blood sugar levels early on can also increase the chance that a baby will be born with a birth defect, such as a spine or heart problem.",
"       </li>",
"       <li>",
"        Later on, high blood sugar levels can increase the chance that a baby gets too big (heavier than 9 pounds). That is a problem, because a big baby can get hurt if it cannot easily fit through the vagina. A big baby can also damage its mother&rsquo;s body during a vaginal delivery. Sometimes, the mother has to have a c-section (surgery to get the baby out).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1479066226\">",
"      <span class=\"h1\">",
"       What doctors will take care of me during pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different doctors will take care of you during pregnancy. One doctor will take care of your pregnancy. This doctor might also be able to take care of your diabetes. If not, you will see your diabetes doctor or nurse during pregnancy. He or she will:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Tell you what your blood sugar levels should be and how often to check them &ndash; Many women need to check their blood sugar levels every day before and after meals.",
"       </li>",
"       <li>",
"        Help you make changes to your diet and medicines so that your blood sugar levels stay under control",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1479066233\">",
"      <span class=\"h1\">",
"       Why might my diabetes medicines need to be changed?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your diabetes medicines might need to be changed because:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Women who take insulin might need more insulin during pregnancy.",
"       </li>",
"       <li>",
"        Some diabetes pills are not safe to take during pregnancy. Women who take these pills need to start using insulin or take a different pill during pregnancy. Your doctor will tell you which medicine is right for you.",
"       </li>",
"       <li>",
"        Women who don&rsquo;t already take medicine for their diabetes might need to start taking a diabetes medicine during pregnancy.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1479066240\">",
"      <span class=\"h1\">",
"       How else might pregnancy affect me?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes, pregnancy worsens the eye and kidney problems that people with diabetes can get. Pregnancy can also make high blood pressure worse. Your doctor will check you for these problems by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Doing blood and urine tests to check your kidneys",
"       </li>",
"       <li>",
"        Doing eye exams",
"       </li>",
"       <li>",
"        Checking your blood pressure at each visit",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1479066247\">",
"      <span class=\"h1\">",
"       Can I have a normal vaginal delivery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Chances are good that you will have a normal vaginal delivery. But women with diabetes are more likely to have a c-section than women without diabetes.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1479066254\">",
"      <span class=\"h1\">",
"       Will my baby be healthy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your blood sugar levels have been under control, chances are good that your baby will be healthy. But your baby&rsquo;s doctor will keep a close eye on your baby. That&rsquo;s because babies whose mothers have diabetes can have problems, including low blood sugar or breathing problems. Most of these problems go away on their own within 1 to 2 days.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1479066261\">",
"      <span class=\"h1\">",
"       What if I am thinking about getting pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are thinking about getting pregnant and have type 1 or type 2 diabetes, talk with your doctor or nurse before you get pregnant. He or she can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Help you get your blood sugar levels under control",
"       </li>",
"       <li>",
"        Make changes to your medicines, if they need to be changed",
"       </li>",
"       <li>",
"        Treat any medical problems you have",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1479066268\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=see_link\">",
"       Patient information: Type 1 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=see_link\">",
"       Patient information: Type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/58/28579?source=see_link\">",
"       Patient information: Using insulin (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/21/16723?source=see_link\">",
"       Patient information: C-section (cesarean delivery) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/45/10966?source=see_link\">",
"       Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/31/35317?source=see_link\">",
"       Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=see_link\">",
"       Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/45/11988?source=see_link\">",
"       Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/62/31714?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15731 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-0E3ADE63EF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_62_31714=[""].join("\n");
var outline_f30_62_31714=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1479066212\">",
"      Can women with type 1 or type 2 diabetes have a healthy pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1479066219\">",
"      What problems can be caused by high blood sugar levels?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1479066226\">",
"      What doctors will take care of me during pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1479066233\">",
"      Why might my diabetes medicines need to be changed?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1479066240\">",
"      How else might pregnancy affect me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1479066247\">",
"      Can I have a normal vaginal delivery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1479066254\">",
"      Will my baby be healthy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1479066261\">",
"      What if I am thinking about getting pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1479066268\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/45/11988?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/21/16723?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/45/10966?source=related_link\">",
"      Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/31/35317?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/58/28579?source=related_link\">",
"      Patient information: Using insulin (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_62_31715="Schematic and 3D echo of mitral valve leaflets";
var content_f30_62_31715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Schematic and 3D echocardiographic image of mitral valve leaflets",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anatomically, the mitral valve is formed by a long and narrow&nbsp;anterior leaflet&nbsp;and a shorter posterior leaflet occupying a larger portion of the annular circumference.",
"    <br>",
"     (A) Anatomical description proposed by Carpentier, with the posterior leaflet divided into anterolateral (P1), middle (P2), and postero-medial (P3) scallops. While the anterior leaflet does not have obvious anatomical divisions, corresponding segments are labeled similarly A1 to A3.",
"     <br>",
"      (B) Corresponding 3D TEE image of the mitral valve as viewed from the left atrial side.",
"      <div class=\"footnotes\">",
"       Ao: aortic valve.",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_62_31715=[""].join("\n");
var outline_f30_62_31715=null;
var title_f30_62_31716="Bag mask technique for edentulous patient";
var content_f30_62_31716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F87227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F87227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Bag mask technique for edentulous patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In edentulous adults, placing the caudad end of the mask between the lower lip and the alveolar ridge may improve ventilation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kathleen Wittels, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_62_31716=[""].join("\n");
var outline_f30_62_31716=null;
var title_f30_62_31717="Coronary artery bypass graft surgery";
var content_f30_62_31717=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/62/31717/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/62/31717/contributors\" id=\"au6237\">",
"       Julian M Aroesty, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/62/31717/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/62/31717/contributors\" id=\"se576\">",
"       Gabriel S Aldea, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/62/31717/contributors\" id=\"se4605\">",
"       Edward Verrier, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/62/31717/contributors\" id=\"se4323\">",
"       Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/62/31717/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/62/31717/contributors\" id=\"de1101\">",
"       Gordon M Saperia, MD, FACC",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/62/31717?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      BYPASS SURGERY OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     In coronary heart disease (CHD), the coronary arteries become clogged with calcium and fatty deposits. The deposits, called plaques, narrow the arteries that carry blood to the heart muscle (",
"     <a class=\"graphic graphic_figure graphicRef78702 \" href=\"mobipreview.htm?3/9/3219\">",
"      figure 1",
"     </a>",
"     ). Blood supplies the heart muscle with oxygen and sources of energy; ischemia (a reduction in blood flow and oxygen) can produce symptoms of pain in the chest (angina pectoris). In more severe cases, heart attack (myocardial infarction), heart failure, or rhythm abnormalities can cause sudden cardiac death.",
"    </p>",
"    <p>",
"     Coronary artery bypass graft surgery, or CABG (pronounced \"cabbage\"), is a procedure that uses your own veins (usually from the legs) or arteries to bypass narrowed areas and restore blood flow to heart muscle. Thus, bypass surgery can effectively relieve chest pain for most patients, and can prolong life for those with certain patterns of severe coronary heart disease.",
"    </p>",
"    <p>",
"     The final decision regarding the best choice of treatment depends upon several factors, including the benefit versus risk of surgery, the severity of your symptoms and cardiac disease, and your underlying medical problems. You should discuss the details of your case with your healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      IS BYPASS SURGERY RIGHT FOR ME?",
"     </span>",
"    </p>",
"    <p>",
"     Surgical treatment may be recommended for different situations:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Stable angina",
"     </span>",
"     &nbsp;&mdash;&nbsp;Angina (chest pain) is considered stable when its frequency, severity, duration, and precipitating factors are not changing. Patients with stable angina may require CABG if there are persistent and intolerable symptoms despite adequate medical treatment, specific patterns of arterial narrowing in several vessels, or patients with a high risk of heart attack and death.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Extensive disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients with extensive CHD, including narrowing of the left main coronary artery, multiple narrowed coronary arteries, and poor pumping function of their left ventricle (lower heart chamber) generally live longer when they undergo CABG as compared to patients who have medical or less invasive (balloon angioplasty or stent) treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Future risk of cardiac event",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients who are identified as having a high risk for a future cardiac event, based on an exercise test. The test may show changes in the electrocardiogram (called ECG or EKG), poor exercise capacity, failure to raise blood pressure during exercise, or severely limited blood flow to multiple areas of the heart. Blood flow is sometimes measured with a myocardial perfusion scan or echocardiogram obtained immediately after exercise.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Unstable angina",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients who develop unstable angina may be candidates for CABG or angioplasty (stent therapy). Angina is considered unstable if it becomes more frequent, occurs with less exertion or at rest, is more severe, lasts longer, or fails to respond to appropriate medication.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      After myocardial infarction",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients who have had a myocardial infarction (heart attack) may undergo CABG if their blood vessels cannot be opened with balloon angioplasty or stent placement. More information on angioplasty is available. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/10/43170?source=see_link&amp;anchor=H4#H4\">",
"      \"Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)\", section on 'Interventional angina treatment'",
"     </a>",
"     .).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      BYPASS SURGERY PROCEDURE",
"     </span>",
"    </p>",
"    <p>",
"     With CABG surgery, a vein or artery taken from elsewhere in the body is grafted from the aorta (the major blood vessel exiting the heart) onto the coronary artery, beyond the narrowed segment. This avoids (bypasses) the diseased section and restores blood flow to the area of the heart muscle supplied by that artery. Multiple grafts may be used if more than one coronary artery is diseased (",
"     <a class=\"graphic graphic_figure graphicRef73589 \" href=\"mobipreview.htm?37/7/38004\">",
"      figure 2",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Choice of graft",
"     </span>",
"     &nbsp;&mdash;&nbsp;Generally, blood vessels can be obtained from four areas of the body: leg, chest, arm, and abdomen.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Saphenous veins are taken from the leg (calf or thigh). Historically, the saphenous vein was the graft of choice. However, narrowing (stenosis) of the vein graft, due to changes that are similar to those of a coronary artery, is a major problem with saphenous vein grafts, causing them to deteriorate within five to seven years in approximately 50 percent of patients. A number of factors may predispose to saphenous vein graft disease if not well controlled, including smoking, hypertension, lipid abnormalities, and diabetes.",
"      </li>",
"      <li>",
"       Internal mammary arteries (also called internal thoracic arteries) are on the left and right side of the breast bone, at the center of the front part of the chest. Unlike vein or radial artery grafts, internal mammary grafts are not fully removed from their original position. These grafts remain connected to their natural site of origin, and only one end is separated from the chest wall. This end is then attached to one of the coronary arteries.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Arterial grafts rarely develop stenosis (narrowing) and have an improved long-term survival compared to vein grafts. In addition, patients with arterial grafts tend to have better survival, fewer reoperations, a lower rate of myocardial infarction (MI), and less recurrent angina, as compared to vein grafts. Fortunately, the left internal mammary artery, or LIMA, runs close to the most important coronary artery, the left anterior descending coronary artery, or LAD. Thus, the most important coronary artery is often bypassed with the most effective type of graft.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Radial arteries are taken from the inner forearm. The long-term outcome with these arteries is also excellent and almost equivalent to that of the internal mammary artery. There are usually only minimal changes in hand function after removal of the radial artery for CABG, which manifest as a small amount of forearm numbness and tingling, but generally no change in motor function or tolerance to temperature or pain. In the majority of these patients, the symptoms are self-limited.",
"      </li>",
"      <li>",
"       The gastroepiploic artery, which comes from the stomach, is another option for grafting. It is currently used rarely, although results with this artery are encouraging.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      The surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Conventional CABG is performed while the patient is under general anesthesia (completely asleep with medication). The surgery generally takes three to six hours. The surgeon makes an incision in the breastbone (sternum), called a median sternotomy, to open the chest and gain access to the heart. If the internal mammary artery is being used, it is separated from the chest wall; if a vein or radial artery is being used, it is removed from the leg or arm.",
"    </p>",
"    <p>",
"     Attaching the bypass vessel to the coronary artery requires the heart to be temporarily stopped using chemicals and cold (hypothermia) so that the surgeon can sew on the grafts.",
"    </p>",
"    <p>",
"     While the heart is stopped, blood circulation is maintained with a heart-lung machine, or cardiopulmonary bypass machine. This functions like the heart and lungs, circulating blood and providing oxygen to the body. Fluids, nutrients, and medications may be added to the blood while it passes through the cardiopulmonary bypass machine.",
"    </p>",
"    <p>",
"     The surgeon sews one end of the graft onto the aorta and the other end to a part of the coronary artery beyond the narrowing, hence bypassing the diseased area.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      New procedures",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several new surgical approaches are now being developed that may reduce the discomforts and risks associated with traditional bypass surgery. Known as \"minimally invasive bypass surgery\" and \"off-pump surgery,\" these approaches use a small chest incision and are performed on the heart while it is still beating. These techniques have become increasingly popular but are not appropriate for all bypass situations. In the hands of surgeons with wide experience using this technique, long-term outcomes seem to be comparable to the standard CABG operation and generally involve a shorter stay in the hospital.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      BYPASS SURGERY RECOVERY",
"     </span>",
"    </p>",
"    <p>",
"     Immediately after surgery, the patient spends one to two days in an intensive care unit. Family members can visit periodically during this time. A number of systems are used to monitor the patient's heart rate and rhythm, blood pressure, temperature, and breathing rate; monitoring is gradually discontinued as the person recovers.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The breathing tube that was placed in the airway before surgery is removed as soon as the patient is awake and able to breathe on their own. Most people awaken within a few hours after surgery. It is common to feel groggy and disoriented during this time.",
"      </li>",
"      <li>",
"       A thin, flexible tube (catheter) is usually placed in the bladder before surgery begins. The catheter is needed to collect and measure urine. Once the person is able to get up and go to the bathroom, the catheter is removed.",
"      </li>",
"      <li>",
"       Fluids, medications, and sometimes blood transfusions are given before, during, and after the surgery through an intravenous (IV) line. When the person is able to eat and drink and no longer requires IV medications, the line is removed.",
"      </li>",
"      <li>",
"       Tubes are placed inside the chest to drain fluids that accumulate around the heart after surgery. These are usually removed within one to three days after surgery.",
"      </li>",
"      <li>",
"       The incision in the chest is usually sore, with the most discomfort in the first 48 to 72 hours after surgery. Pain medications are usually given to relieve discomfort.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     When continuous monitoring is no longer required, usually after 12 to 24 hours, most patients are moved to a step-down or transitional care unit. Most people can sit in a chair the day after surgery. The person is encouraged to start walking within one to two days after surgery.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Many people have a poor appetite for several weeks after surgery. This is normal and expected. Talk to a doctor or nurse if there are concerns about appetite.",
"      </li>",
"      <li>",
"       Constipation is also common during this time, probably due to decreased activity and food intake and use of pain medications. Medications to relieve constipation may be recommended. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/10/34977?source=see_link\">",
"        \"Patient information: Constipation in adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       People who have a graft harvested from the leg sometimes notice swelling in this leg after surgery. Elevating the leg and wearing compression stockings can help to reduce swelling.",
"      </li>",
"      <li>",
"       It is common to have difficulty sleeping after bypass surgery, especially while in the hospital. This usually improves after discharge from the hospital.",
"      </li>",
"      <li>",
"       Approximately 20 to 40 percent of people become depressed after CABG. Signs of depression include sadness for most of the day, diminished pleasure or interest in almost all activities, insomnia or excessive sleep, or feelings of worthlessness or guilt. Depression can interfere with recovery and increase the risk of heart problems in the future. Anyone who notes signs of depression that last for more than two weeks should speak to their healthcare provider about treatment options. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/41/20116?source=see_link\">",
"        \"Patient information: Depression in adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Most people recover in the hospital for four to five days after surgery. However, hospitalization may be longer, depending upon an individual's rate of recovery and any complications that develop.",
"    </p>",
"    <p>",
"     People who do not have complications or a prolonged hospital stay are usually able to return to desk work within four to six weeks. People who have a physically demanding job often need more time to recover. Complete recovery from surgery often takes two to three months. Care at home after surgery is discussed in a separate topic review (see",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/16/23813?source=see_link\">",
"      \"Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)\"",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      BYPASS SURGERY COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     There are a number of complications that can occur after CABG. The major complications include bleeding that may require a return to the operating room, heart attack, heart failure, arrhythmia, stroke, changes in cognitive function, pulmonary problems, wound infection, renal failure, and death.",
"    </p>",
"    <p>",
"     Postoperative complications may be related to the body's response to artificial blood circulation and gas exchange through the cardiopulmonary bypass apparatus.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Cardiac complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many complications affect the heart directly.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Two to four percent of patients experience electrocardiographic or enzyme evidence of a heart attack after surgery, which generally is small to moderate in size. This occurs less frequently in patients who are low risk as compared to patients who are high risk. High risk patients include those undergoing repeat CABG, or those who need CABG combined with other cardiac surgery. Generally postoperative heart attacks are small to moderate in size.",
"      </li>",
"      <li>",
"       Especially in patients with some damage to the heart muscle prior to CABG, low cardiac output (when a reduced volume of blood is pumped out of the heart to the body) can occur during or after surgery. This is often temporary and responds to intravenous fluids",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       a brief period of therapy to improve heart function. Therapy may include medications or a special mechanical device that can augment the heart's ability to contract (intraaortic balloon pump or left ventricular assist device).",
"      </li>",
"      <li>",
"       Tachyarrhythmias, temporary rapid",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       irregular heart rhythms, may occur after CABG.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Atrial fibrillation, an abnormal rhythm of the heart, occurs in up to 40 percent of cases but can be controlled with medications. This rhythm disturbance may cause a blood clot to develop within the heart. If this blood clot becomes dislodged, it can travel to another organ in the body, such as the brain, resulting in a stroke. Atrial fibrillation after CABG is usually temporary; if persistent, patients may require longer term treatment. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/16/261?source=see_link\">",
"      \"Patient information: Atrial fibrillation (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Sustained ventricular tachycardia (a rapid and regular heart beat) or ventricular fibrillation (a rapid, chaotic, and ineffective heart beat) occurs in approximately 2 to 3 percent of patients, usually within four days of surgery. An automatic internal defibrillator may be needed for selected patients. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/20/11589?source=see_link\">",
"      \"Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Postoperative bradyarrhythmias cause the heart to beat too slowly and require placement of a permanent pacemaker in 0.8 to 4 percent of patients. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/16/20741?source=see_link\">",
"      \"Patient information: Pacemakers (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Pericarditis is an inflammation of the pericardium, the sac that surrounds the heart. Sometimes pericarditis is accompanied by pericardial effusion, in which the pericardial sac fills up with fluid. If a large amount of fluid accumulates in the pericardium, it may push on and squeeze or constrict the heart, called cardiac tamponade. In that case, the fluid can generally be removed with a needle.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Pericarditis often causes chest pain, which generally occurs a few days to several weeks after surgery. Pericardial effusions are usually small and resolve without treatment. If the effusion is large, urgent treatment or reoperation may be needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Bleeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Approximately 30 percent of patients require a blood transfusion after CABG. Patients with heavy bleeding that requires reoperation often need multiple blood transfusions and stay longer in the intensive care unit and hospital. Only about 2 percent of people require surgery to stop excessive bleeding.",
"    </p>",
"    <p>",
"     One factor that increases the risk of postoperative bleeding is exposure to aspirin in the week before surgery. However, some patients should continue aspirin therapy before CABG to maintain its beneficial effect. Plavix&reg; (clopidogrel) and ibuprofen are generally discontinued for several days prior to coronary surgery. Patients taking warfarin (Coumadin&reg;) should speak with their surgeon about how and when to stop it before surgery. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=see_link\">",
"      \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Neurologic complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Neurologic complications include stroke, postoperative delirium, short-term and long-term cognitive changes, and depression. The incidence of neurologic problems following CABG is approximately 2 to 4 percent; older patients and women are affected more frequently.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;The surgical sites involved in CABG can become infected after the surgery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Sternal wound",
"     </span>",
"     &nbsp;&mdash;&nbsp;Infection of the chest incision (called the sternal wound) occurs in approximately 1 percent of patients. It usually develops by 7 to 9 days after surgery. Diabetes mellitus, obesity, and the use of both left and right internal mammary arteries increase the risk of sternal wound infection. Women with a history of breast cancer are at especially high risk, possibly related to therapies used during breast cancer treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Leg wounds",
"     </span>",
"     &nbsp;&mdash;&nbsp;Leg wounds develop complications after saphenous vein graft harvesting in approximately 5 percent of patients. The most common complications include dermatitis (inflammation of the skin), cellulitis (a bacterial infection of the skin), nerve damage, and non-healing ulcers; most are minor and do not require surgical intervention.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Renal failure",
"     </span>",
"     &nbsp;&mdash;&nbsp;A temporary decrease in kidney function occurs in approximately 5 to 10 percent of patients undergoing CABG.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Other complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of other complications may occur as well.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Pleural effusions &mdash; Pleural effusions are collections of fluid in the membranes surrounding the lungs. These are common after CABG, occurring in up to 90 percent of patients. They are usually small and do not require treatment.",
"      </li>",
"      <li>",
"       Phrenic nerve damage &mdash; The phrenic nerve, the nerve that controls the diaphragm, is damaged during CABG in less than 1 percent of patients. Damage can cause diaphragm dysfunction or paralysis. Most people recover fully within one year.",
"      </li>",
"      <li>",
"       Intercostal nerve damage &mdash; The intercostal nerves are connected to the thorax and abdomen. Harvesting the internal mammary artery can injure these nerves. Symptoms of nerve damage include numbness, tenderness, or burning discomfort over the sternum and left anterolateral chest wall. Pain usually subsides by four months.",
"      </li>",
"      <li>",
"       Aortic dissection &mdash; Aortic dissection, a disorder in which the layers of tissue that make up the aorta split apart, can occur after CABG. People who are elderly, have longstanding high blood pressure, severely narrowed coronary arteries, or widening of the aorta are at greater risk.",
"      </li>",
"      <li>",
"       Thrombocytopenia &mdash; Heparin is given during CABG to prevent the blood from clotting during and after the procedure. In some cases, heparin can cause a decrease in the number of platelets in the blood (called thrombocytopenia), which can decrease clotting ability and increase the risk of bleeding. If needed, other medications may be used to induce anticoagulation without producing thrombocytopenia.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      LONG-TERM OUTCOME",
"     </span>",
"    </p>",
"    <p>",
"     As mentioned above, patients with symptomatic angina who undergo CABG can have greatly improved outcomes.",
"    </p>",
"    <p>",
"     There are a number of factors that influence the long-term outcome of a patient that has undergone CABG. One of these is how patent, or open, the graft remains over time. If the grafts do not remain open, an angioplasty or another operation may be needed. The choice of graft, as discussed above, can greatly influence the need for reoperation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Angina after surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;About 95 percent of people who have narrowing of several arteries have improvement or complete relief of their angina immediately after surgery. About 85 to 90 percent of people remain angina-free at one to three years after surgery, and about 75 percent of people remain angina-free or free of major coronary events at five years after surgery.",
"    </p>",
"    <p>",
"     Reasons for recurrence of angina include",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Narrowing that develops in the graft used for the bypass.",
"      </li>",
"      <li>",
"       Progression of disease in the bypassed or non-bypassed vessels.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The recurrence of angina is less frequently seen when the vessel used for the bypass is an artery as compared to a vein. By 10 years, 90 percent of arterial grafts are still open; in contrast, about one-half of all vein grafts become narrowed or occluded at 10 years after bypass surgery, and by 15 years, about 85 percent of vein grafts become narrowed or occluded. These late events, which are often associated with recurrence of symptoms, usually require a second revascularization procedure, most often done with angioplasty or stent placement, and less often with a repeat surgical bypass.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H24\">",
"     <span class=\"h1\">",
"      CARE AFTER BYPASS SURGERY",
"     </span>",
"    </p>",
"    <p>",
"     Cardiac recovery and care is discussed in detail in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/16/23813?source=see_link\">",
"      \"Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413361681\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H185760770\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/10/27809?source=see_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/53/10068?source=see_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/27/21940?source=see_link\">",
"      Patient information: Medicines after a heart attack (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/49/34577?source=see_link\">",
"      Patient information: Cardiac tamponade (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H185760778\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/10/43170?source=see_link\">",
"      Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/10/34977?source=see_link\">",
"      Patient information: Constipation in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/41/20116?source=see_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/16/23813?source=see_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/16/261?source=see_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/20/11589?source=see_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/16/20741?source=see_link\">",
"      Patient information: Pacemakers (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=see_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31576?source=see_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=see_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6617?source=see_link\">",
"      Coronary artery bypass grafting in patients with cerebrovascular disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39368?source=see_link\">",
"      Early cardiac complications of coronary artery bypass graft surgery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=see_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=see_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/38/30310?source=see_link\">",
"      Minimally invasive aortic and mitral valve surgery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37031?source=see_link\">",
"      Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3834?source=see_link\">",
"      Neurologic complications of cardiac surgery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1800?source=see_link\">",
"      Postoperative mediastinitis after cardiac surgery",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"      www.nhlbi.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americanheart.org/\">",
"      www.americanheart.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Society of Thoracic Surgeons",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.sts.org/\">",
"      www.sts.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/62/31717/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 11, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/62/31717?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31717/abstract/1\">",
"      Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31717/abstract/2\">",
"      Pires LA, Wagshal AB, Lancey R, Huang SK. Arrhythmias and conduction disturbances after coronary artery bypass graft surgery: epidemiology, management, and prognosis. Am Heart J 1995; 129:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31717/abstract/3\">",
"      Peduzzi P, Kamina A, Detre K. Twenty-two-year follow-up in the VA Cooperative Study of Coronary Artery Bypass Surgery for Stable Angina. Am J Cardiol 1998; 81:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31717/abstract/4\">",
"      Fitzgibbon GM, Kafka HP, Leach AJ, et al. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996; 28:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31717/abstract/5\">",
"      Myers WO, Blackstone EH, Davis K, et al. CASS Registry long term surgical survival. Coronary Artery Surgery Study. J Am Coll Cardiol 1999; 33:488.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f30_62_31717=[""].join("\n");
var outline_f30_62_31717=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           BYPASS SURGERY OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           IS BYPASS SURGERY RIGHT FOR ME?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           BYPASS SURGERY PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           BYPASS SURGERY RECOVERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           BYPASS SURGERY COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           LONG-TERM OUTCOME",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H24\">",
"           CARE AFTER BYPASS SURGERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/9/3219\" title=\"figure 1\">",
"           Plaque formation PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/7/38004\" title=\"figure 2\">",
"           CABG PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f30_62_31718="Evaluation for infection before solid organ transplantation";
var content_f30_62_31718=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation for infection before solid organ transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/62/31718/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/62/31718/contributors\">",
"     Jay A Fishman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/62/31718/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/62/31718/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/62/31718/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/62/31718/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/62/31718/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solid organ transplantation has become the therapy of choice for a variety of types of organ failure. Two major complications, infection and malignancy, are the result of the life-long immunosuppression needed to maintain allograft function.",
"   </p>",
"   <p>",
"    The organisms most commonly associated with post-transplant infection are the result of reactivation of latent infection carried by the donor organ or the recipient, or are due to new exposures in the community or in the hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31718/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Latent infection refers to organisms residing in a suppressed state in the recipient or in the donor tissue. Cytomegalovirus, Epstein-Barr virus, Toxoplasma gondii, Strongyloides stercoralis, and Trypanosoma cruzi are examples of organisms that can exist in the normal host and are, in general, controlled by the host immune system. The risk for reactivation (replication) of any latent infection is related to the nature and intensity of the immune suppression following transplantation.",
"   </p>",
"   <p>",
"    Colonization with pathogens that may be resistant to multiple antimicrobial agents is common in patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cystic fibrosis or other forms of chronic lung disease",
"     </li>",
"     <li>",
"      Cardiomyopathy",
"     </li>",
"     <li>",
"      Cirrhosis",
"     </li>",
"     <li>",
"      Those awaiting organ replacement with lengthy hospitalizations",
"     </li>",
"     <li>",
"      Multiple exposures to broad-spectrum antimicrobial agents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Colonizing organisms may include Pseudomonas aeruginosa, Aspergillus species, Stenotrophomonas maltophilia, Burkholderia cepacia, methicillin-resistant staphylococci, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant enterococci. These organisms are potential pathogens in the setting of immune suppression or acutely in the postoperative setting if acquired from the environment via vascular access catheters, endotracheal tubes, or open surgical wounds.",
"   </p>",
"   <p>",
"    Established infection is difficult to treat in the immunocompromised transplant recipient. Significant antimicrobial toxicities are common, often due to diminished renal or hepatic function and drug interactions. Every effort must be made to detect and to eliminate any such potential pathogens whenever possible prior to transplantation or to design effective prophylactic strategies to prevent the reemergence of latent infections after transplantation. The pretransplant evaluation is central to the prevention of postoperative infection.",
"   </p>",
"   <p>",
"    The components of the pretransplant evaluation will be reviewed here. The infections that follow solid organ transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/29/10714?source=see_link\">",
"     \"Prophylaxis of infections in solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31207?source=see_link\">",
"     \"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/26/12712?source=see_link\">",
"     \"Tuberculosis in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16842?source=see_link\">",
"     \"Infectious complications in liver transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12778?source=see_link\">",
"     \"Bacterial infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/6/3178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15914?source=see_link\">",
"     \"Fungal infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40084?source=see_link\">",
"     \"Differential diagnosis of infection following renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical evaluation of a patient prior to solid organ transplantation should focus on exposure history, cultures for colonization, serologies for more distant exposures, and administration of vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31718/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed history must uncover exposures to organisms that may be of importance in the immunocompromised host. In addition, a careful review of systems may uncover current occult infection or colonization. Historical features should include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Travel history or residence in areas of the world with unique endemic infections (Strongyloides stercoralis, Trypanosoma spp, Schistosoma spp, Leishmania spp, Histoplasma capsulatum, Coccidioides immitis, or Blastomyces dermatitidis, hepatitis viruses, mycobacteria)",
"     </li>",
"     <li>",
"      Pets including cats, dogs, rodents or birds such as parakeets (eg, Psittacosis)",
"     </li>",
"     <li>",
"      Unusual exposures such as well water, unpasteurized dairy products, or imported cheeses (eg, Cryptosporidium or Listeria monocytogenes)",
"     </li>",
"     <li>",
"      Employment and hobbies including exposures to soil, birds, and toxins (endemic fungi, atypical mycobacteria)",
"     </li>",
"     <li>",
"      History of urinary tract infections or prostatitis (chronic infections, reflux)",
"     </li>",
"     <li>",
"      History of sexually transmitted diseases",
"     </li>",
"     <li>",
"      High-risk behaviors for human immunodeficiency virus (HIV) exposure",
"     </li>",
"     <li>",
"      Vaccinations and childhood illnesses",
"     </li>",
"     <li>",
"      Prior surgery such as splenectomy, porta",
"      <strong>",
"       -",
"      </strong>",
"      systemic shunting, or sinus surgery",
"     </li>",
"     <li>",
"      Drug and alcohol use",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Special consideration should be given to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exposure to mycobacterial infection, especially Mycobacterium tuberculosis, BCG vaccination, and the results of previous tuberculin skin testing or interferon-gamma release assays",
"     </li>",
"     <li>",
"      Past history of Salmonella or Toxoplasma infections",
"     </li>",
"     <li>",
"      Past history of hepatitis or peritonitis",
"     </li>",
"     <li>",
"      Prior hospitalizations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prior infections should be documented, including the antimicrobial susceptibility pattern of each organism previously isolated and any treatments received. In addition, transplant candidates with recurrent infections such as cholecystitis, sinusitis, pyelonephritis, diverticulitis, Crohn's disease, or Helicobacter pylori-positive ulcer disease should have these conditions resolved, even surgically if necessary, prior to transplantation. Anatomic predispositions to infection should also be identified including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vesicoureteral reflux",
"     </li>",
"     <li>",
"      Sinus obstruction",
"     </li>",
"     <li>",
"      Cardiac valvular abnormalities",
"     </li>",
"     <li>",
"      Intravascular clot",
"     </li>",
"     <li>",
"      Prosthetic biomaterials such as vascular grafts, artificial joints, dialysis access fistulae, or catheters",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A history of recent immunosuppressive regimens such as glucocorticoids for systemic lupus erythematosus or autoimmune hepatitis and past treatment for malignancy which can alter the choice and intensity of both prophylactic and immunosuppressive regimens after transplantation. The use of immunosuppressive therapies in the pretransplant period can increase the risk of Pneumocystis jirovecii (formerly P. carinii) pneumonia or toxoplasmosis in the early posttransplant period. Previously treated malignancies which have an infectious etiology, such as anogenital carcinoma due to papilloma virus or nasopharyngeal carcinoma or Burkitt's lymphoma associated with EBV, are more likely to relapse after transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing for evidence of past infectious exposures or active infections is performed to determine the risk for infection in the transplant recipient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31718/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Some tests are suggested for all patients, whereas others are useful in selected patients with suggestive epidemiologic risk factors (",
"    <a class=\"graphic graphic_table graphicRef59792 \" href=\"mobipreview.htm?31/17/32028\">",
"     table 1",
"    </a>",
"    ). Serologic testing is used as an indicator of prior infections. Antibody-based tests (serologic tests) should not, in general, be used for the diagnosis of active infections since there may be a delay between pathogen exposure and seroconversion (&ldquo;window period&rdquo;). Nucleic acid tests (NAT) are used to detect and measure active infections in organ donors or recipients and generally will be positive earlier in infection compared with serologic assays. Potential recipients should be screened for:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HIV-1 and -2",
"     </li>",
"     <li>",
"      Hepatitis A, B, and C",
"     </li>",
"     <li>",
"      Cytomegalovirus (CMV)",
"     </li>",
"     <li>",
"      Epstein-Barr virus (EBV)",
"     </li>",
"     <li>",
"      Herpes simplex virus (HSV)",
"     </li>",
"     <li>",
"      Varicella-zoster virus (VZV)",
"     </li>",
"     <li>",
"      Syphilis (Venereal Disease Research Laboratory [VDRL] or rapid plasma reagin [RPR])",
"     </li>",
"     <li>",
"      Toxoplasma gondii (in heart transplant candidates)",
"     </li>",
"     <li>",
"      Human T-lymphotropic virus (HTLV)-I and HTLV-II (no longer required in the United States)",
"     </li>",
"     <li>",
"      Tuberculosis (tuberculin skin testing or interferon-gamma release assay [IGRA])",
"     </li>",
"     <li>",
"      Serologic tests for Strongyloides stercoralis, Coccidioides spp, Leishmania spp,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      Trypanosoma cruzi (in candidates with exposure to endemic areas)",
"     </li>",
"     <li>",
"      Stool ova and parasites for S. stercoralis (in candidates with exposure to endemic areas)",
"     </li>",
"     <li>",
"      Urine ova and parasites (and cystoscopy) for Schistosoma spp (for kidney transplant candidates with exposure to endemic areas)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Screening for CMV, HSV, VZV, toxoplasmosis, and Chagas disease are used as guides for prophylactic strategies after transplantation rather than for pretransplant therapies. EBV serologies are useful in stratifying the risk for post-transplant lymphoproliferative disorders (PTLD), particularly among pediatric recipients who are at the highest risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Viral load testing should be obtained for HIV, hepatitis B and C in infected candidates. Routine peritransplant prophylaxis for hepatitis B is advocated for unvaccinated liver transplant recipients with active infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/29/10714?source=see_link\">",
"     \"Prophylaxis of infections in solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/37/1625?source=see_link\">",
"     \"Hepatitis B virus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Particular note must be made of tuberculosis testing and of the pretransplant treatment of patients with positive serologies for Strongyloides. In endemic regions, donors and recipients may be screened for exposure to West Nile virus, Chagas disease, or other unique pathogens (",
"    <a class=\"graphic graphic_table graphicRef59792 \" href=\"mobipreview.htm?31/17/32028\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/26/12712?source=see_link\">",
"     \"Tuberculosis in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vaccinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of infection through immunization is of paramount importance to the increasing population of solid organ transplant recipients. However, many immunocompromised patients are unable to mount protective immune responses to vaccines. Furthermore, immunization with live virus vaccines may result in unchecked proliferation of attenuated vaccine strains and is therefore generally avoided in solid organ transplant recipients. For these reasons, it is optimal to immunize patients prior to transplantation. Vaccine recommendations for solid organ transplant candidates and recipients are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Testing for latent tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of tuberculosis in solid organ transplant recipients is 20 to 74 times higher than in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31718/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. The vast majority of cases are due to reactivation disease, although infection via a transplanted organ has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31718/abstract/4\">",
"     4",
"    </a>",
"    ]. Tuberculin skin testing (TST) is recommended, although anergy is common in this population and some authors recommend routine retesting if the first reaction is negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31718/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Some authors advocate the use of the interferon-gamma release assays (IGRAs) in the detection of latent tuberculosis. In practice, it is unclear whether IGRA testing is significantly better than standard TST testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31718/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Radiographic changes on chest films can also be suggestive of prior exposure to tuberculosis.",
"   </p>",
"   <p>",
"    Indications for prophylaxis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recent TST conversion or positive IGRA",
"     </li>",
"     <li>",
"      A history of tuberculosis contact before transplantation",
"     </li>",
"     <li>",
"      Recipients of transplants from donors with a history of untreated tuberculosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who completed a course of adequate therapy for tuberculosis in the past do not need repeat prophylaxis unless they have one of the last two indications above.",
"   </p>",
"   <p>",
"    Screening and treatment of latent tuberculosis in solid organ transplant candidates and recipients are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/26/12712?source=see_link\">",
"     \"Tuberculosis in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Active infections in the transplant candidate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active bacterial and fungal infections must be eliminated, whenever possible, prior to transplantation. Even asymptomatic infections can evolve into overwhelming sepsis following transplantation. As an example, lung transplant candidates with cystic fibrosis will generally be colonized with organisms resistant to antimicrobial agents such as Pseudomonas aeruginosa, Staphylococcus spp, and Burkholderia cepacia. Since manipulation of the infected lung tissue during transplantation theoretically could disseminate infection, bactericidal and fungicidal therapies are initiated prior to transplantation. B. cenocepacia appears to be a particularly virulent genomovar of B. cepacia. Management of lung transplant candidates and recipients who are colonized with this organism is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12778?source=see_link&amp;anchor=H1627022308#H1627022308\">",
"     \"Bacterial infections following lung transplantation\", section on 'Burkholderia cepacia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Control of infection in hepatic retransplantation for technical problems (bile leaks, infarcts) raises similar difficulties. Infection must be treated to the degree possible prior to transplant surgery. The resolution of infection should be documented, including reimaging with interventional sampling to assure drainage and sterilization of infected fluids or repeat bronchoscopic cultures, prior to \"activation\" of the candidate on the transplant waiting list.",
"   </p>",
"   <p>",
"    As noted above, patients with an anatomic predisposition to infection such as cholecystitis or diverticulitis may need preemptive surgery prior to transplantation. Patients with a history of recurrent sinusitis should be evaluated for sinus infections by computed tomography and an otolaryngologist with culture specimens obtained sterilely",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drainage procedures, if needed, performed prior to transplantation.",
"   </p>",
"   <p>",
"    Whenever possible, all intravenous or urinary catheters should be removed as soon as is possible, but certainly discontinued prior to transplantation. Exceptions include hemodialysis or peritoneal dialysis catheters in the nonbacteremic patient and intra-aortic balloon pumps. However, these should be removed, if possible, at the time of transplantation. In patients with liver failure awaiting transplantation, elective intubation may be performed to prevent aspiration. Sputum specimens should be cultured frequently in these patients. Antimicrobial prophylaxis against spontaneous bacterial peritonitis, generally with a fluoroquinolone agent, is useful in patients with ascites after documentation of negative cultures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31718/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/1/4121?source=see_link\">",
"     \"Treatment and prophylaxis of spontaneous bacterial peritonitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Perioperative surgical prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of specific data about colonization or infection due to resistant organisms in an individual patient, standard perioperative antimicrobial prophylaxis is administered for solid organ transplantation. Regimens including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (except in cardiac transplant recipients) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    should be avoided whenever possible, to decrease the risk of colonization with vancomycin-resistant organisms and the latter to lessen the chance of developing diarrhea due to Clostridium difficile postoperatively.",
"   </p>",
"   <p>",
"    Generally, 24 hours or less of a first-generation cephalosporin provides adequate protection for renal transplantation in the absence of specific microbiologic data that would require broader coverage. In hepatic transplantation, coverage is generally employed for biliary and bowel flora including enterococci and anaerobic organisms, in addition to antifungal prophylaxis. Generally, antifungal prophylaxis with azole drugs is used for patients requiring a Roux-en-Y loop or for pancreas transplant recipients based upon the higher incidence of candidal infection in these hosts. Many centers with a significant rate of infection due to Aspergillus after liver or lung transplantation use perioperative prophylaxis with a lipid formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , inhaled amphotericin products, or later generation azoles (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ). The azole antifungals have significant effects on the metabolism of calcineurin inhibitors and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ; dose adjustments must be made during and after such therapies.",
"   </p>",
"   <p>",
"    More detailed recommendations for the use of perioperative prophylaxis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/29/10714?source=see_link&amp;anchor=H6#H6\">",
"     \"Prophylaxis of infections in solid organ transplantation\", section on 'Prophylaxis peritransplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H155046031\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The organisms most commonly associated with post-transplant infection are the result of reactivation of latent infection carried by the donor organ or the recipient, or are due to new exposures in the community or in the hospital. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Latent infection refers to organisms residing in a suppressed state in the recipient or in the donor tissue. Cytomegalovirus, Epstein-Barr virus, Toxoplasma gondii, Strongyloides stercoralis, and Trypanosoma cruzi are examples of organisms that can exist in the normal host and are, in general, controlled by the host immune system. All of these pathogens may cause life-threatening infection in the immunocompromised host. The risk for reactivation of any latent infection is related to the nature and intensity of the immune suppression following transplantation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Colonizing organisms may include Pseudomonas aeruginosa, Aspergillus species, Stenotrophomonas maltophilia, Burkholderia cepacia, methicillin-resistant staphylococci, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      -resistant enterococci. These organisms are potential pathogens in the setting of immune suppression or acutely in the postoperative setting if acquired from the environment via vascular access catheters, endotracheal tubes, or open surgical wounds. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pretransplant evaluation is central to the prevention of postoperative infection. The clinical evaluation of a patient prior to solid organ transplantation should focus on exposure history, cultures for colonization, serologies for more distant exposures, and administration of vaccines. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A detailed history must uncover exposures to organisms that may be of importance in the immunocompromised host (eg, travel and residence history, pets, occupational and recreational exposures, high risk behaviors). In addition, a careful review of systems may uncover current occult infection or colonization. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory testing for evidence of past infectious exposures is performed to detect asymptomatic infection in the transplant candidate. Some tests are suggested for all patients, whereas others are useful in selected patients with epidemiologic risk factors (",
"      <a class=\"graphic graphic_table graphicRef59792 \" href=\"mobipreview.htm?31/17/32028\">",
"       table 1",
"      </a>",
"      ). Serologic testing is used as an indicator of significant past exposures; screening for cytomegalovirus, herpes simplex virus, varicella zoster virus, and toxoplasmosis are used as guides for prophylactic strategies after transplantation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is optimal to immunize patients prior to transplantation. Vaccine recommendations for solid organ transplant candidates and recipients are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/48/23306?source=see_link\">",
"       \"Immunizations in solid organ transplant candidates and recipients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Perioperative antimicrobial prophylaxis is used to prevent infection in the early post-transplant period. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Perioperative surgical prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/29/10714?source=see_link&amp;anchor=H6#H6\">",
"       \"Prophylaxis of infections in solid organ transplantation\", section on 'Prophylaxis peritransplantation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31718/abstract/1\">",
"      Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31718/abstract/2\">",
"      Avery RK. Recipient screening prior to solid-organ transplantation. Clin Infect Dis 2002; 35:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31718/abstract/3\">",
"      Avery RK. Prophylactic strategies before solid-organ transplantation. Curr Opin Infect Dis 2004; 17:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31718/abstract/4\">",
"      Fischer SA, Avery RK, AST Infectious Disease Community of Practice. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant 2009; 9 Suppl 4:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31718/abstract/5\">",
"      Mu&ntilde;oz P, Rodr&iacute;guez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005; 40:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31718/abstract/6\">",
"      Aguado JM, Torre-Cisneros J, Fort&uacute;n J, et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009; 48:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31718/abstract/7\">",
"      Manuel O, Humar A, Preiksaitis J, et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007; 7:2797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31718/abstract/8\">",
"      Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998; 27:1266.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1398 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-E01451B0F0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_62_31718=[""].join("\n");
var outline_f30_62_31718=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H155046031\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vaccinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Testing for latent tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Active infections in the transplant candidate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Perioperative surgical prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H155046031\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1398\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1398|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/17/32028\" title=\"table 1\">",
"      Pretransplant lab evaluation SOT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12778?source=related_link\">",
"      Bacterial infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/6/3178?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40084?source=related_link\">",
"      Differential diagnosis of infection following renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15914?source=related_link\">",
"      Fungal infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/37/1625?source=related_link\">",
"      Hepatitis B virus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/48/23306?source=related_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16842?source=related_link\">",
"      Infectious complications in liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31207?source=related_link\">",
"      Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/59/6073?source=related_link\">",
"      Prevention of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/29/10714?source=related_link\">",
"      Prophylaxis of infections in solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/1/4121?source=related_link\">",
"      Treatment and prophylaxis of spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/26/12712?source=related_link\">",
"      Tuberculosis in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_62_31719="Cipro crystals kidney bx";
var content_f30_62_31719=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph of kidney biopsy with ciprofloxacin crystals within tubular lumen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 539px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Hematoxylin and eosin staining shows needle-shaped stellate crystals. B) Ciprofloxacin crystals within the tubule polarize.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stratta, P, Lazzarich, E, Canavese, C, et al. Ciprofloxacin crystal nephropathy. Am J Kidney Dis 2007; 50:330. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_62_31719=[""].join("\n");
var outline_f30_62_31719=null;
var title_f30_62_31720="Clinical manifestations and diagnosis of Candida infection in neonates";
var content_f30_62_31720=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of Candida infection in neonates",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/62/31720/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/62/31720/contributors\">",
"     Mohan Pammi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/62/31720/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/62/31720/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/62/31720/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/62/31720/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/62/31720/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida has emerged as an important cause of neonatal infections with significant morbidity and mortality, especially in extremely low and very low birth weight infants, defined as birth weights below 1000 g and 1500 g, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The clinical manifestations of Candida infection in the neonate varies ranging from localized infections of the skin and mucous membranes to life-threatening systemic infection with multisystem organ failure. Host risk factors, such as prematurity and the use of invasive procedures, are important determinants that influence the severity and type of neonatal Candida infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of Candida infection in the neonate will be reviewed here. The etiology, treatment, and prevention of neonatal candidal infections are discussed separately, as are the clinical manifestations of Candida in older infants and children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24039?source=see_link\">",
"     \"Epidemiology and risk factors for Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40760?source=see_link\">",
"     \"Treatment of Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31481?source=see_link\">",
"     \"Overview of Candida infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The various presentations of Candida infections in the newborn can be separated into the following categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mucocutaneous candidiasis, which includes oropharyngeal involvement (thrush) or diaper dermatitis.",
"     </li>",
"     <li>",
"      Systemic candidiasis typically due to catheter-related or localized infections that progress to disseminated infections and multi-organ involvement.",
"     </li>",
"     <li>",
"      Catheter-related infections without multi-organ involvement.",
"     </li>",
"     <li>",
"      Invasive focal infection including meningitis, urinary tract infections, peritonitis, endophthalmitis, osteomyelitis, and septic arthritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although Candida albicans is the major candidal species isolated from neonates with candidal infection, other species such as C. parapsilosis, C. tropicalis, and fluconazole-resistant C. glabrata can also cause neonatal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/1,6,7\">",
"     1,6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24039?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and risk factors for Candida infection in neonates\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The immaturity of host defenses and the compromise of the epithelial barrier are the primary pathogenetic factors for neonatal candidal infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24039?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology and risk factors for Candida infection in neonates\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MUCOCUTANEOUS CANDIDIASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucocutaneous candidiasis is a candidal infection of the skin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mucous membranes. It includes oropharyngeal candidiasis (thrush), diaper dermatitis, congenital candidiasis, and invasive fungal dermatitis. Mucocutaneous candidiasis has the potential to disseminate via the blood stream to other organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Prematurity and breaks in the epithelial barriers, (eg, indwelling catheters) are major risk factors for systemic dissemination of mucocutaneous disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24039?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and risk factors for Candida infection in neonates\", section on 'Risk factors for invasive candidiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Oropharyngeal candidiasis (thrush)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oropharyngeal candidiasis is a common manifestation of Candida infection throughout infancy both in preterm and healthy fullterm infants. Among hospitalized infants in the neonatal intensive care unit (NICU), an overall incidence of oropharyngeal candidiasis of 3 percent has been reported at a median age of onset of 9 to 10 days of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maternal vaginal candidal colonization and birth asphyxia are reported risk factors associated with oropharyngeal candidiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/12\">",
"     12",
"    </a>",
"    ]. Although oropharyngeal candidiasis can be transmitted during breastfeeding, the incidence of this condition appears to be greater in infants who are formula-fed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thrush presents as irregular white plaques with or without an erythematous base on the buccal or lingual mucosal surface of the mouth. Most infants remain asymptomatic, however, some infants may refuse to eat because of discomfort from contact with their lesion(s) during feeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diaper dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although diaper dermatitis can occur throughout infancy, the peak incidence is 7 to 10 months of age in term infants. However, rash in the diaper area is a common manifestation of mucocutaneous candidiasis in the premature infant. In one review, 8 percent of very low birth weight infants (birth weight below 1500 g) developed mucocutaneous candidiasis during their initial NICU admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/10\">",
"     10",
"    </a>",
"    ]. This study also demonstrated that premature infants with candidal diaper dermatitis who have a change in their clinical status were at increased risk for developing systemic infection. Infants with candidal diaper dermatitis are also more likely to have candidal colonization of their gastrointestinal tract.",
"   </p>",
"   <p>",
"    Candidal diaper dermatitis is characterized by an area of confluent erythema in the inguinal region, discrete erythematous papules and plaques with superficial scales, and satellite lesions. (",
"    <a class=\"graphic graphic_picture graphicRef59361 graphicRef72165 \" href=\"mobipreview.htm?35/41/36501\">",
"     picture 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Invasive fungal dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive fungal dermatitis is a unique condition described in extremely low birth weight premature infants (birth weight below 1000 g) during the first two weeks of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/9,15\">",
"     9,15",
"    </a>",
"    ]. The lesions vary in appearance. They include macular, papular, vesicular, or pustular lesions that are typically in dependent or intertriginous areas of the skin. The erosions can be extensive and sometimes involve the whole area of the abdomen or back.",
"   </p>",
"   <p>",
"    Skin biopsy is diagnostic and shows Candida hyphae invading the dermis. Dissemination of infection to the bloodstream is common.",
"   </p>",
"   <p>",
"    In one series of 16 infants with this condition, postnatal steroids and hyperglycemia were implicated as risk factors; 69 percent had evidence of disseminated fungal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Congenital candidiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital cutaneous candidiasis is a rare disorder that results from a Candida spp. infection acquired in utero or during delivery. The risk of ascending infection is increased by ruptured membranes, presence of a uterine or cervical foreign body, and a history of vaginal candidiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The affected infant typically presents on the first day of life with a generalized eruption of 2 to 4 mm erythematous macules",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    papules that rest upon a 5 to 10 mm erythematous base. These lesions evolve into pustules, vesicles, or even bullae (",
"    <a class=\"graphic graphic_picture graphicRef68825 \" href=\"mobipreview.htm?23/51/24370\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/16,18\">",
"     16,18",
"    </a>",
"    ]. Unlike erythema toxicum neonatorum or miliaria, this condition is characterized by the frequent involvement of the palms and soles. Oral thrush may be present at birth, and yellow-white papules may be observed on the umbilical cord.",
"   </p>",
"   <p>",
"    In term infants, the skin lesions generally resolve with desquamation by the first week of life. Since the disease in these infants is usually limited to the skin, it can be treated successfully with topical antifungal agents and close surveillance. Occasionally, term babies with congenital candidiasis have systemic manifestations, such as pneumonia or clinical evidence of sepsis, which require systemic antifungal therapy.",
"   </p>",
"   <p>",
"    In preterm infants, the rash may have a variable presentation including widespread pustular and vesicular lesions, or diffuse erythematous macular patches resembling a burn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/19\">",
"     19",
"    </a>",
"    ]. Crusting of the skin may be the presenting feature of such cases. Cultures for fungus should be obtained of blood, urine,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CSF. Demonstration of budding yeast and pseudohyphae, usually in large numbers, on a potassium hydroxide preparation of scrapings from the skin lesions is helpful in making the diagnosis. Skin biopsy may be needed in some cases. Premature infants with congenital candidiasis have a greater risk for systemic infection and should be treated for candidemia until culture results are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/16,20\">",
"     16,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SYSTEMIC INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature infants, particularly extremely low birth weight infants (birth weight less than 1000 g), are at increased risk for developing candidemia because of the immaturity of their immune and host epithelial protection, compromise of their epithelial protection with invasive procedures (eg, intubation, central venous catheters,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery), and factors that promote increased density of candidal colonization (eg, administration of broad-spectrum antibiotics). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24039?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and risk factors for Candida infection in neonates\", section on 'Risk factors for invasive candidiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study from the National Nosocomial Infections Surveillance, the overall attack rate of candidal blood stream infections was 1.53 per 1000 patient days among infants admitted to the NICU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/4\">",
"     4",
"    </a>",
"    ]. As the gestational age decreased, the risk of candidemia increased. Thus extremely low birth infants (birth weight less than 1000 g) had the highest risk of candidemia with an incidence of 2.68 per 1000 patient days. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24039?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and risk factors for Candida infection in neonates\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presentation of neonatal candidemia can vary depending upon the extent of systemic disease. The most common presentation is similar to that of bacterial sepsis. Symptoms include lethargy, feeding intolerance, hyperbilirubinemia, apnea, cardiovascular instability,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory distress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/14,21\">",
"     14,21",
"    </a>",
"    ]. In the most severe cases, cardiorespiratory function is severely compromised with multi-organ failure. The combination of persistent hyperglycemia and thrombocytopenia is strongly associated with candidemia and, if present, a diagnosis of candidemia should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hallmark of candidemia is the involvement of multiple organ systems, especially in low birth weight infants. Infants with multi-organ failure have a poor prognosis. The diagnosis of a candidal infection of any one organ system should prompt a thorough examination and evaluation to detect candidemia and other organ involvement. Although any organ can be involved, the most common sites include the eye, urinary tract, heart, and the central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. These focal sites of infection are discussed separately in the following sections. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Invasive focal infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Skin abscesses, which appear as clusters of painless pustules on an erythematous base or nodules, have been described in neonates with candidemia and are thought to be caused by septic emboli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CATHETER-RELATED INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants who have indwelling catheters in place for greater than seven days are at risk for developing a catheter-related candidal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/20\">",
"     20",
"    </a>",
"    ]. Infected catheters are a major cause and risk factor for disseminated disease.",
"   </p>",
"   <p>",
"    Infants with catheter-related infections will exhibit nonspecific symptoms of sepsis (eg, temperature instability, feeding intolerance, apnea, and hyperglycemia) but without any evidence of multi-organ involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, thrombocytopenia is a common finding. An infected thrombus or fungal ball can form on the catheter tip, which consumes platelets and is a source of septic emboli.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INVASIVE FOCAL INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the newborn, invasive focal infection is generally due to seeding of the individual organ system from hematogenous dissemination. As a result, if a candidal infection is diagnosed that involves the urinary tract, central nervous system, eye, bone, or joints, the infant should be evaluated for systemic fungal infection as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/23,25\">",
"     23,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cultures of the blood, urine, and cerebral spinal fluid (CSF)",
"     </li>",
"     <li>",
"      Dilated eye examination",
"     </li>",
"     <li>",
"      An echocardiogram to determine whether there is any evidence of cardiac thrombi or vegetations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Diagnostic imaging of the liver, spleen, and kidney",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of urinary tract infection (UTI) due to a Candida is approximately 0.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In the NICU, Candida is a common cause of UTI in infants. In one case series of 57 infants with 60 documented UTIs, Candida was responsible for 25 of the 60 infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The spectrum of clinical manifestations of candidal UTI ranges from Candida cystitis in infants with indwelling urinary catheters to parenchymal renal disease from candidemia. In several case series, the reported renal involvement ranged from 5 to 33 percent of infants with candidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/6,23,28\">",
"     6,23,28",
"    </a>",
"    ]. In the above mentioned case series of infants with UTI cared for in the NICU, candidemia was present in 13 of 25 cases of candidal UTI. In a prospective cohort study conducted in 13 Canadian NICUs, 30 infants with Candida UTI developed extra-renal candidiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for candidal UTI include congenital anomalies of the kidney and urinary tract, obstruction, urinary stasis, and the presence of an indwelling bladder catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/27,28,30\">",
"     27,28,30",
"    </a>",
"    ]. Clinical manifestations of candidal UTI are generally nonspecific and include apnea, bradycardia, glucose intolerance, and decreased urine output. In some cases, specific urinary tract findings occur and include urinary tract obstruction, hypertension, or renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/31-34\">",
"     31-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of candidal UTI is based upon a positive urine culture. A candidal UTI is present if there are any to greater than 1000",
"    <span class=\"nowrap\">",
"     CFU/mL",
"    </span>",
"    in a specimen collected by suprapubic aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/26\">",
"     26",
"    </a>",
"    ] or greater than 10,000",
"    <span class=\"nowrap\">",
"     CFU/mL",
"    </span>",
"    in a specimen collected by catheterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As discussed previously, any infant diagnosed with a candidal UTI should be evaluated for systemic infection as they are at risk for candidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasonography is useful to detect any renal parenchymal infiltration, calyceal mycetoma, or fungal masses (ie, fungal balls) in the urinary tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/27,28,30\">",
"     27,28,30",
"    </a>",
"    ]. In addition, renal ultrasonography is used to screen for congenital anomalies of the kidney and urinary tract.",
"   </p>",
"   <p>",
"    In one retrospective review of neonates with candidemia, abdominal ultrasonography detected abnormalities due to Candida in the kidneys in 3 of 65 (5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/23\">",
"     23",
"    </a>",
"    ]. Lesions may not be present at the initial study but may become evident on subsequent examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/27\">",
"     27",
"    </a>",
"    ]. In infants with oliguria, obstruction due to discrete fungal masses can be detected by ultrasonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Serial studies are also used to follow the response to therapy and the resolution of fungal masses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Central nervous system infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system (CNS) infections are generally the result of hematogenous spread of Candida and usually presents as meningitis. Other uncommon presentations of candidal CNS involvement include brain abscesses, ventriculitis, vasculitis, and fungal masses within the subarachnoid space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CNS involvement is common in infants with disseminated infections. The reported incidence varies with a range between 10 to 64 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. This variability is primarily due to differences in the degree and thoroughness of detecting CNS disease. In the largest case series that included 106 cases of neonatal systemic candidiasis, 23 infants had candidal meningitis (22 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/38\">",
"     38",
"    </a>",
"    ]. The median gestational age of these patients was 26.2 weeks with a median birth weight of 820 g, and the median age at onset of illness was eight days of life.",
"   </p>",
"   <p>",
"    The initial presentation of CNS varies from a subacute, indolent illness, which is only identified because of a high index of suspicion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/27\">",
"     27",
"    </a>",
"    ], to severe illness with cardiorespiratory instability and multi-organ failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/38\">",
"     38",
"    </a>",
"    ]. Clinical signs may be the same as in an acute bacterial meningitis. These include temperature instability, irritability, poor feeding or vomiting, respiratory distress, and apnea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7928?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features and diagnosis of bacterial meningitis in the neonate\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Findings on cerebral spinal fluid (CSF) are variable and relate to the type of CNS involvement (meningeal versus parenchymal disease). Normal CSF chemistries, cell count, and gram stain do not exclude CNS involvement because the inflammatory response may be limited or delayed, and the inoculum of the organism may be low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/37,38,40\">",
"     37,38,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some infants, parenchymal abscesses were initially diagnosed by cranial imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications due to CNS infection include obstructive hydrocephalus requiring shunt placement, cerebral atrophy, and poor neurodevelopmental outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several case reports or small case series that have reported candidal peritonitis in low birth weight premature infants (birth weight less than 1500 g) with necrotizing enterocolitis or focal gastrointestinal perforations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/20,42-45\">",
"     20,42-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In particular, spontaneous intestinal perforation (SIP) is associated with disseminated candidal infection. This was illustrated in one small case series of premature infants with SIP, in which 33 percent of the affected infants had Candida isolated from a culture of blood, peritoneal fluid, CSF, or urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/42\">",
"     42",
"    </a>",
"    ]. In these cases, pathologic examination of the perforated intestinal area demonstrated fungal invasion of the mucosa. It is unclear whether the perforation is due to a primary candidal invasion of the mucosa or whether Candida is only a colonizing organism that invades the bowel wall that was already damaged from a primary insult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/39/41591?source=see_link\">",
"     \"Clinical features and diagnosis of necrotizing enterocolitis in newborns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"Candida endophthalmitis\" is often used to describe both Candida chorioretinitis (minimal or no vitreous inflammation) and endophthalmitis (marked vitritis), although the correct term to include both is \"ocular candidiasis\". However, \"Candida endophthalmitis\" is the more commonly used term in the ophthalmology literature and, therefore, is also used in this discussion.",
"   </p>",
"   <p>",
"    In the neonate, endophthalmitis results from the hematogenous spread of Candida to the eye. The reported incidence varies from 6 to 50 percent of premature infants with disseminated candidiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/23,39,46\">",
"     23,39,46",
"    </a>",
"    ]. In the largest case series that included 86 infants with candidemia, 4 of the 67 infants (6 percent) in whom indirect ophthalmoscopy examination was performed had retinal abnormalities indicative of candidal infections.",
"   </p>",
"   <p>",
"    Indirect ophthalmoscopy examination must be performed to make the diagnosis of candidal chorioretinitis in all infants with suspected or proven candidemia, because affected neonates may not present with any clinical signs or symptoms and endophthalmitis if not treated may lead to limitation in vision. The classic ophthalmologic findings are focal, glistening, white, infiltrative, often mound-like lesions on the retina with indistinct borders (",
"    <a class=\"graphic graphic_picture graphicRef58685 \" href=\"mobipreview.htm?25/1/25630\">",
"     picture 3",
"    </a>",
"    ). Vitreous extension occurs occasionally and can be seen as a vitreal haze or as fluffy white balls (\"snowballs\") within in the vitreous (",
"    <a class=\"graphic graphic_picture graphicRef73318 \" href=\"mobipreview.htm?24/39/25214\">",
"     picture 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39112?source=see_link\">",
"     \"Treatment of endogenous endophthalmitis due to Candida species\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Candidemia without endophthalmitis appears to be associated with an increased risk of developing severe retinopathy of prematurity (ROP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/23,47-51\">",
"     23,47-51",
"    </a>",
"    ]. Although one study did not find any association with ROP after controlling for gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/52\">",
"     52",
"    </a>",
"    ], several other studies have shown an association between candidal sepsis and ROP requiring laser surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/48,50,51\">",
"     48,50,51",
"    </a>",
"    ]. Thus, based upon the available data, premature infants of any gestational age who develop candidemia should be followed closely by an ophthalmologist for the late development of severe ROP that may require surgical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Osteoarticular infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the neonate, Candida osteomyelitis or arthritis rarely occurs as an isolated event and typically occurs because of disseminated infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. The signs and symptoms of these infections caused by Candida are similar to those that occur in septic arthritis or osteomyelitis caused by bacteria (ie, swelling and decreased range of motion).",
"   </p>",
"   <p>",
"    To distinguish fungal from bacterial infection, the diagnosis is dependent upon isolating Candida from either cultures of the synovial fluid or bone aspirate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candidal endocarditis is a common complication of candidemia. In one retrospective review of 86 infants with candidemia, echocardiogram demonstrated thrombi or vegetations in 11 of 72 infants (15 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/23\">",
"     23",
"    </a>",
"    ]. Infants with fungemia that lasted five or more days were more likely to have cardiac lesions, as well as renal or ophthalmologic abnormalities. Although in this study, the presence of a central venous catheter was not associated with an increased risk of cardiac involvement, other studies, particularly in adult patients, have demonstrated an increased risk of candidal endocarditis associated with the presence of an indwelling catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31481?source=see_link&amp;anchor=H1198646#H1198646\">",
"     \"Overview of Candida infections in children\", section on 'Endocarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of neonatal candidal infection is dependent upon the presentation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who are suspected to have systemic disease or with invasive focal infection, diagnosis is made by isolating a Candida species from the blood, CSF, urine, or other body fluid (",
"      <a class=\"graphic graphic_picture graphicRef50344 \" href=\"mobipreview.htm?40/12/41167\">",
"       picture 5",
"      </a>",
"      ) . Because the sensitivity of a single blood culture is low in detecting disseminated candidiasis, multiple or repeat blood cultures should be performed to increase the likelihood of detecting candidemia. If a central venous catheter is present, cultures should be obtained through the catheter and a peripheral vessel to distinguish between disseminated infection and catheter-related candidiasis.",
"     </li>",
"     <li>",
"      A drawback of all blood culture systems as the primary means of establishing the diagnosis of candidemia is that one to four days are required for growth of the organism. While awaiting culture results, empiric systemic antifungal agents should be administered.",
"     </li>",
"     <li>",
"      Molecular diagnostic methods based on amplification of fungal ribosomal DNA in blood samples are under evaluation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/62/31720/abstract/57,58\">",
"       57,58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with oropharyngeal candidiasis and diaper dermatitis, topical antifungal agents are initiated based upon the clinical diagnosis. Thus, it is usually not necessary to culture any lesion. In infants who fail topical therapy, a culture may be useful to identify the Candida species and assess its sensitivity to the antifungal agent used.",
"     </li>",
"     <li>",
"      In patients with invasive fungal dermatitis, a clinical diagnosis can be made based upon the characteristic skin lesions. A definitive diagnosis is confirmed by a skin biopsy with isolation or histologic identification of the organism.",
"     </li>",
"     <li>",
"      In patients with congenital candidiasis, a presumptive diagnosis can be made by identifying the organism by gram stain of the vesicular contents or by potassium hydroxide preparations of skin scrapings (",
"      <a class=\"graphic graphic_picture graphicRef79879 \" href=\"mobipreview.htm?27/37/28242\">",
"       picture 6",
"      </a>",
"      ). Confirmation of the diagnosis is made with isolation of the organism from a culture of the discrete lesions, or swabs of the affected skin areas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida has emerged as a common cause of infections in infants admitted to the neonatal intensive care unit (NICU), particularly preterm infants.",
"   </p>",
"   <p>",
"    The different presentations of Candida infections in the newborn can be separated into the following categories.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mucocutaneous candidiasis is candidal infection of the skin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mucous membranes. It includes oropharyngeal candidiasis (thrush), diaper dermatitis, congenital candidiasis, and invasive fungal dermatitis. Mucocutaneous candidiasis has the potential to disseminate via the blood stream to other organs, especially in premature infants with either congenital candidiasis or invasive fungal dermatitis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mucocutaneous candidiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic infection is disseminated infection through the bloodstream that results in multi-organ infection. Premature infants, particularly extremely low birth weight infants (birth weight less than 1000 g) are at increased risk for developing candidemia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Systemic infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Catheter-related infection is a major cause of disseminated systemic infection. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Catheter-related infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Invasive focal infection is generally due to seeding of the individual organ system from hematogenous dissemination. Although any organ can be involved, the most common infected sites include the eye, urinary tract, heart, and the central nervous system. In infants with a sterile body fluid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urine culture positive for Candida, further evaluation is recommended to detect disseminated invasive focal infection. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Invasive focal infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of Candida infections is dependent upon the presentation. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of oropharyngeal candidiasis (thrush) and diaper dermatitis is made based upon the clinical presentation of the characteristic findings of these candidal infections. Treatment is initiated based upon the clinical diagnosis.",
"     </li>",
"     <li>",
"      The diagnosis of systemic disease or invasive focal infection is made by isolating a Candida species from the blood, cerebral spinal fluid, urine, or other body fluid.",
"     </li>",
"     <li>",
"      In patients with invasive fungal dermatitis and congenital candidiasis, a presumptive diagnosis is made based upon the clinical presentation. Confirmation is made by histologic identification or isolation of the organism from tissue samples (eg, biopsy or skin scrapings) from the skin.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/1\">",
"      Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J 1998; 17:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/2\">",
"      Beck-Sague CM, Azimi P, Fonseca SN, et al. Bloodstream infections in neonatal intensive care unit patients: results of a multicenter study. Pediatr Infect Dis J 1994; 13:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/3\">",
"      Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/4\">",
"      Fridkin SK, Kaufman D, Edwards JR, et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 2006; 117:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/5\">",
"      Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000; 19:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/6\">",
"      Faix RG. Invasive neonatal candidiasis: comparison of albicans and parapsilosis infection. Pediatr Infect Dis J 1992; 11:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/7\">",
"      Fairchild KD, Tomkoria S, Sharp EC, Mena FV. Neonatal Candida glabrata sepsis: clinical and laboratory features compared with other Candida species. Pediatr Infect Dis J 2002; 21:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/8\">",
"      Rowen JL. Mucocutaneous candidiasis. Semin Perinatol 2003; 27:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/9\">",
"      Rowen JL, Atkins JT, Levy ML, et al. Invasive fungal dermatitis in the &lt; or = 1000-gram neonate. Pediatrics 1995; 95:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/10\">",
"      Faix RG, Kovarik SM, Shaw TR, Johnson RV. Mucocutaneous and invasive candidiasis among very low birth weight (less than 1,500 grams) infants in intensive care nurseries: a prospective study. Pediatrics 1989; 83:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/11\">",
"      Gupta P, Faridi MM, Rawat S, Sharma P. Clinical profile and risk factors for oral candidosis in sick newborns. Indian Pediatr 1996; 33:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/12\">",
"      Daftary SS, Desai SV, Shah MV, Daftary SN. Oral thrush in the new-born. Indian Pediatr 1980; 17:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/13\">",
"      Hoppe JE. Treatment of oropharyngeal candidiasis and candidal diaper dermatitis in neonates and infants: review and reappraisal. Pediatr Infect Dis J 1997; 16:885.",
"     </a>",
"    </li>",
"    <li>",
"     Bendel CM. Candidiasis. In: Infectious diseases of the Fetus and Newborn Infant, 7th ed, Remington JS et al (Ed), Elsevier Saunders, Philadelphia 2010. p.1055.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/15\">",
"      Melville C, Kempley S, Graham J, Berry CL. Early onset systemic Candida infection in extremely preterm neonates. Eur J Pediatr 1996; 155:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/16\">",
"      Darmstadt GL, Dinulos JG, Miller Z. Congenital cutaneous candidiasis: clinical presentation, pathogenesis, and management guidelines. Pediatrics 2000; 105:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/17\">",
"      Roqu&eacute; H, Abdelhak Y, Young BK. Intra amniotic candidiasis. Case report and meta-analysis of 54 cases. J Perinat Med 1999; 27:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/18\">",
"      Almeida Santos L, Beceiro J, Hernandez R, et al. Congenital cutaneous candidiasis: report of four cases and review of the literature. Eur J Pediatr 1991; 150:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/19\">",
"      Baley, JE, Rivers, A, Clapp, DW. Two year outcome of systemic candidiasis in VLBW infants. Ped Res 1988; 23:441A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/20\">",
"      Butler KM, Baker CJ. Candida: an increasingly important pathogen in the nursery. Pediatr Clin North Am 1988; 35:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/21\">",
"      Baley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in very low-birth-weight infants: clinical manifestations and epidemiology. Pediatrics 1984; 73:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/22\">",
"      Dyke MP, Ott K. Severe thrombocytopenia in extremely low birthweight infants with systemic candidiasis. J Paediatr Child Health 1993; 29:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/23\">",
"      Noyola DE, Fernandez M, Moylett EH, Baker CJ. Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia. Clin Infect Dis 2001; 32:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/24\">",
"      Bodey GP, Luna M. Skin lesions associated with disseminated candidiasis. JAMA 1974; 229:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/25\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/26\">",
"      Phillips JR, Karlowicz MG. Prevalence of Candida species in hospital-acquired urinary tract infections in a neonatal intensive care unit. Pediatr Infect Dis J 1997; 16:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/27\">",
"      Bryant K, Maxfield C, Rabalais G. Renal candidiasis in neonates with candiduria. Pediatr Infect Dis J 1999; 18:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/28\">",
"      Benjamin DK Jr, Fisher RG, McKinney RE Jr, Benjamin DK. Candidal mycetoma in the neonatal kidney. Pediatrics 1999; 104:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/29\">",
"      Robinson JL, Davies HD, Barton M, et al. Characteristics and outcome of infants with candiduria in neonatal intensive care - a Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. BMC Infect Dis 2009; 9:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/30\">",
"      Karlowicz MG. Candidal renal and urinary tract infection in neonates. Semin Perinatol 2003; 27:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/31\">",
"      Eckstein CW, Kass EJ. Anuria in a newborn secondary to bilateral ureteropelvic fungus balls. J Urol 1982; 127:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/32\">",
"      Khan MY. Anuria from candida pyelonephritis and obstructing fungal balls. Urology 1983; 21:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/33\">",
"      McDonnell M, Lam AH, Isaacs D. Nonsurgical management of neonatal obstructive uropathy due to Candida albicans. Clin Infect Dis 1995; 21:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/34\">",
"      Sirinelli D, Biriotti V, Schmit P, et al. Urinoma and arterial hypertension complicating neonatal renal candidiasis. Pediatr Radiol 1987; 17:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/35\">",
"      Wynn JL, Tan S, Gantz MG, et al. Outcomes following candiduria in extremely low birth weight infants. Clin Infect Dis 2012; 54:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/36\">",
"      Friedman S, Richardson SE, Jacobs SE, O'Brien K. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J 2000; 19:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/37\">",
"      Faix RG. Systemic Candida infections in infants in intensive care nurseries: high incidence of central nervous system involvement. J Pediatr 1984; 105:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/38\">",
"      Fernandez M, Moylett EH, Noyola DE, Baker CJ. Candidal meningitis in neonates: a 10-year review. Clin Infect Dis 2000; 31:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/39\">",
"      Chen JY. Neonatal candidiasis associated with meningitis and endophthalmitis. Acta Paediatr Jpn 1994; 36:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/40\">",
"      Cohen-Wolkowiez M, Smith PB, Mangum B, et al. Neonatal Candida meningitis: significance of cerebrospinal fluid parameters and blood cultures. J Perinatol 2007; 27:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/41\">",
"      Faix RG, Chapman RL. Central nervous system candidiasis in the high-risk neonate. Semin Perinatol 2003; 27:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/42\">",
"      Adderson EE, Pappin A, Pavia AT. Spontaneous intestinal perforation in premature infants: a distinct clinical entity associated with systemic candidiasis. J Pediatr Surg 1998; 33:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/43\">",
"      Robertson NJ, Kuna J, Cox PM, Lakhoo K. Spontaneous intestinal perforation and Candida peritonitis presenting as extensive necrotizing enterocolitis. Acta Paediatr 2003; 92:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/44\">",
"      Kaplan M, Eidelman AI, Dollberg L, Abu-Dalu K. Necrotizing bowel disease with candida peritonitis following severe neonatal hypothermia. Acta Paediatr Scand 1990; 79:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/45\">",
"      Mintz AC, Applebaum H. Focal gastrointestinal perforations not associated with necrotizing enterocolitis in very low birth weight neonates. J Pediatr Surg 1993; 28:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/46\">",
"      Baley JE, Annable WL, Kliegman RM. Candida endophthalmitis in the premature infant. J Pediatr 1981; 98:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/47\">",
"      Mittal M, Dhanireddy R, Higgins RD. Candida sepsis and association with retinopathy of prematurity. Pediatrics 1998; 101:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/48\">",
"      Noyola DE, Bohra L, Paysse EA, et al. Association of candidemia and retinopathy of prematurity in very low birthweight infants. Ophthalmology 2002; 109:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/49\">",
"      Tadesse M, Dhanireddy R, Mittal M, Higgins RD. Race, Candida sepsis, and retinopathy of prematurity. Biol Neonate 2002; 81:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/50\">",
"      Haroon Parupia MF, Dhanireddy R. Association of postnatal dexamethasone use and fungal sepsis in the development of severe retinopathy of prematurity and progression to laser therapy in extremely low-birth-weight infants. J Perinatol 2001; 21:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/51\">",
"      Bharwani SK, Dhanireddy R. Systemic fungal infection is associated with the development of retinopathy of prematurity in very low birth weight infants: a meta-review. J Perinatol 2008; 28:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/52\">",
"      Karlowicz MG, Giannone PJ, Pestian J, et al. Does candidemia predict threshold retinopathy of prematurity in extremely low birth weight (&lt;/=1000 g) neonates? Pediatrics 2000; 105:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/53\">",
"      Swanson H, Hughes PA, Messer SA, et al. Candida albicans arthritis one year after successful treatment of fungemia in a healthy infant. J Pediatr 1996; 129:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/54\">",
"      Harris MC, Pereira GR, Myers MD, et al. Candidal arthritis in infants previously treated for systemic candidiasis during the newborn period: report of three cases. Pediatr Emerg Care 2000; 16:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/55\">",
"      Ward RM, Sattler FR, Dalton AS Jr. Assessment of antifungal therapy in an 800-gram infant with candidal arthritis and osteomyelitis. Pediatrics 1983; 72:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/56\">",
"      Mayayo E, Moralejo J, Camps J, Guarro J. Fungal endocarditis in premature infants: case report and review. Clin Infect Dis 1996; 22:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/57\">",
"      Briones, CR, Villanueva-Uy, ME, Uy, HG. The use of polymerase chain reaction in neonatal candidemia. Pediatr Res 2003; 53:396A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31720/abstract/58\">",
"      Tirodker UH, Nataro JP, Smith S, et al. Detection of fungemia by polymerase chain reaction in critically ill neonates and children. J Perinatol 2003; 23:117.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5024 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-D8E73D39BC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_62_31720=[""].join("\n");
var outline_f30_62_31720=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MUCOCUTANEOUS CANDIDIASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Oropharyngeal candidiasis (thrush)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diaper dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Invasive fungal dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Congenital candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SYSTEMIC INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CATHETER-RELATED INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INVASIVE FOCAL INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Central nervous system infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Peritonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Osteoarticular infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5024\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5024|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/53/13136\" title=\"picture 1A\">",
"      Candidal diaper dermatitis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/53/4945\" title=\"picture 1B\">",
"      Candidal diaper dermatitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/51/24370\" title=\"picture 2\">",
"      Congenital cutaneous candidiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/1/25630\" title=\"picture 3\">",
"      Candida endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/39/25214\" title=\"picture 4\">",
"      Vitritis in endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/12/41167\" title=\"picture 5\">",
"      Candida albicans culture plate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/37/28242\" title=\"picture 6\">",
"      Hyphae candida albicans",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7928?source=related_link\">",
"      Clinical features and diagnosis of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/39/41591?source=related_link\">",
"      Clinical features and diagnosis of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24039?source=related_link\">",
"      Epidemiology and risk factors for Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31481?source=related_link\">",
"      Overview of Candida infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40760?source=related_link\">",
"      Treatment of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39112?source=related_link\">",
"      Treatment of endogenous endophthalmitis due to Candida species",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_62_31721="Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management";
var content_f30_62_31721=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/62/31721/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/62/31721/contributors\">",
"     C Michael Gibson, MS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/62/31721/contributors\">",
"     Joseph P Carrozza, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/62/31721/contributors\">",
"     Roger J Laham, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/62/31721/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/62/31721/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/62/31721/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/62/31721/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/62/31721/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H24755908\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary reperfusion with primary percutaneous coronary intervention (PCI) improves outcomes in patients with acute ST elevation myocardial infarction (STEMI) or an MI with a new or presumably new left bundle branch block or a true posterior MI if performed in a timely fashion. Most procedures are now performed with drug-eluting stents, which are associated with a lower rate of restenosis than bare-metal stents. A concern about a somewhat higher rate of subacute stent thrombosis relative to bare metal stents exists, but ongoing trials should effectively address this issue. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will address some of the technical aspects of PCI, as well as adjunctive medications when used in the periprocedural period. Issues related to the performance of primary PCI will be reviewed here. The determinants of outcome, the clinical trials demonstrating the benefit of primary PCI compared to fibrinolytic therapy, selection of a reperfusion strategy, the possible role of PCI after fibrinolysis, and the role of PCI in non-ST elevation acute coronary syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29961?source=see_link\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/31/37369?source=see_link\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/42/34473?source=see_link\">",
"     \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1366171\">",
"    <span class=\"h1\">",
"     PCI AFTER FIBRINOLYTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCI after fibrinolytic therapy may be indicated in patients who remain unstable or in stable patients who have had incomplete reperfusion. This issue is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/42/34473?source=see_link\">",
"     \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1365622\">",
"    <span class=\"h1\">",
"     TECHNICAL ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32226860\">",
"    <span class=\"h2\">",
"     Radial versus femoral approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients undergoing primary PCI, we prefer the radial to the femoral approach if performed by skilled operators.",
"   </p>",
"   <p>",
"    Bleeding complications are common in patients with STEMI and they predict a worse prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/1\">",
"     1",
"    </a>",
"    ]. Many of these major bleeds occur in relation to the access site for PCI, particularly when the femoral artery is used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38666?source=see_link&amp;anchor=H24#H24\">",
"     \"Periprocedural complications of percutaneous coronary intervention\", section on 'Access site bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early reports suggested that procedural access using the radial as opposed to the femoral artery had the potential to decrease the frequency of bleeding complications in patients with acute coronary syndromes (ACS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. These early findings were substantiated in the RIVAL and RIFLE-STEACS trials.",
"   </p>",
"   <p>",
"    In a prespecified subgroup analysis of the RIVAL trial, which compared the two approaches in patients with ACS, the primary composite outcome of death, MI, stroke, or non-coronary artery bypass graft related major bleeding was lower with the radial approach in patients with ST-segment elevation MI (hazard ratio 0.60, 95% CI 0.38-0.94) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38666?source=see_link&amp;anchor=H59456800#H59456800\">",
"     \"Periprocedural complications of percutaneous coronary intervention\", section on 'Radial artery access'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two approaches were directly compared in the RIFLE-STEACS trial in which 1001 patients with STEMI undergoing",
"    <span class=\"nowrap\">",
"     primary/rescue",
"    </span>",
"    PCI were randomly assigned to a radial or femoral approach; operators were skilled in both approaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/6\">",
"     6",
"    </a>",
"    ]. The primary composite endpoint of cardiac death, stroke, MI, target lesion revascularization, and bleeding at 30 days occurred less frequently with radial access (13.6 versus 21.0 percent; p = 0.003), attributable principally to significantly lower rates of cardiac mortality (5.2 versus 9.2 percent) and bleeding (7.8 versus 12.2 percent). The decrease in bleeding occurred mostly at the access site and was accompanied by a lower rate of transfusion.",
"   </p>",
"   <p>",
"    Two large registry reports support the findings of the RIVAL and RIFLE-STEACS trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis of matched pair of patients in the REAL (Italy) multicenter registry (n-11,068), the two-year risk adjusted mortality and vascular complication (need for surgery or blood transfusion) rates were significantly lower with the transradial approach (8.8 versus 11.4 percent and 1.1 versus 2.5 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an analysis of 90,897 patients in the (US) CathPCI Registry (2007 to 2011), the adjusted risk of bleeding was significantly lower with a transradial approach (odds ratio [OR] 0.62, 95% CI 0.53-0.72) as was the risk of in-hospital mortality (OR 0.76, 95% CI 0.57-099) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24756041\">",
"    <span class=\"h2\">",
"     Direct stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of low-profile stent delivery systems has led to the consideration of direct stenting (ie, without predilation). Advantages of direct stenting include less radiation exposure and contrast use, as well as shorter procedural times. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24889?source=see_link&amp;anchor=H8#H8\">",
"     \"General principles of the use of intracoronary stents\", section on 'Optimal stenting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with an acute STEMI undergoing primary PCI, direct stenting may also reduce embolization of plaque constituents, lowering the incidence of the no-reflow phenomenon, thereby increasing myocardial perfusion and salvage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=see_link&amp;anchor=H4#H4\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\", section on 'No-reflow phenomenon'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of this approach was best evaluated in a randomized trial of 206 patients with an acute STEMI who underwent primary stenting with or without predilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/9\">",
"     9",
"    </a>",
"    ]. Although the incidence of TIMI flow grade 3 and the corrected TIMI frame count were the same with both approaches, the incidence of the composite angiographic endpoint (slow and no reflow or distal embolization) was significantly lower with direct stenting (12 versus 27 percent with predilation before stenting) and ST segment resolution was more frequent (80 versus 62 percent).",
"   </p>",
"   <p>",
"    Additional but weak evidence of benefit comes from a (nonrandomized) cohort study of 2528 patients with ST-elevation myocardial infarction enrolled in the HORIZONS-AMI trial who underwent either direct stenting (28 percent) or predilation at the operator&rsquo;s discretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link&amp;anchor=H21647881#H21647881\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Bivalirudin'",
"    </a>",
"    .) At one-year follow-up, direct stenting was associated with a significantly lower rate of all-cause death (1.6 versus 3.8 percent).",
"   </p>",
"   <p>",
"    Direct stenting also may improve myocardial perfusion and the incidence of death, MI, or heart failure compared to conventional stenting in patients who undergo PCI after fibrinolysis. This was illustrated in an observational study in which the choice of procedure was at the discretion of the treating physician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/10\">",
"     10",
"    </a>",
"    ]. Among patients with occluded infarct-related arteries, the likelihood of achieving TIMI myocardial perfusion grade 3 was significantly greater with direct stenting (54 versus 25 percent with conventional stenting). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7786?source=see_link&amp;anchor=H6#H6\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'TIMI myocardial perfusion grade'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8634?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\", section on 'Rescue PCI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest performing direct stenting of the culprit lesion in most cases. Aspiration thrombectomy is a useful strategy prior to direct stenting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=see_link\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Contraindications to direct stenting include heavy calcification of the vessel or poor visualization of the distal edge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24756048\">",
"    <span class=\"h2\">",
"     Selection of stent type",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-eluting stents (DES) are used in preference to bare-metal stents (BMS) in many PCI procedures because they reduce the incidence of restenosis and target vessel revascularization without causing a significant increase in the cumulative rate of adverse outcomes in many patient groups. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1081?source=see_link&amp;anchor=H348517385#H348517385\">",
"     \"Drug-eluting compared to bare metal intracoronary stents\", section on 'DES compared to BMS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, rates of stent thrombosis are higher for first generation stents than BMS and there has been a concern that the magnitude of the difference could be greater in patients with STEMI, where the baseline risk of stent thrombosis is higher than in patients with stable disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=see_link&amp;anchor=H165352083#H165352083\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Impact of ACS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on the evidence presented below, we believe that the use of either DES or BMS is reasonable for patients undergoing primary PCI who are able to comply with a recommendation for one year of dual antiplatelet therapy. Thus, we agree with the 2011 guideline from the American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Society",
"    </span>",
"    for Cardiovascular Angiography and Interventions which state that it is reasonable to use a DES as an alternative to a BMS for primary PCI in STEMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/13\">",
"     13",
"    </a>",
"    ]. For patients receiving DES, we prefer second generation to first generation DES in most cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H626162715\">",
"    <span class=\"h3\">",
"     First generation DES compared to BMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar outcomes between first generation DES and BMS have been shown in patients with acute ST elevation myocardial infarction (STEMI) undergoing primary PCI. However, since patients with an acute MI (within 48 to 72 hours) were excluded from the pivotal trials, primary PCI has been considered an \"off-label\" use in the United States. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1081?source=see_link\">",
"     \"Drug-eluting compared to bare metal intracoronary stents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/62/16360?source=see_link\">",
"     \"Comparison of drug-eluting intracoronary stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many randomized trials, including TYPHOON, PASSION, SESAMI, DEDICATION, and HORIZONS AMI have evaluated outcomes at one year or less [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/14-19\">",
"     14-19",
"    </a>",
"    ]. They suggest that the lower rate of restenosis of sirolimus-eluting or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -eluting stents relative to BMS, when used for primary PCI, is similar to that in other settings.",
"   </p>",
"   <p>",
"    Longer-term outcomes comparing DES to BMS have been evaluated in multiple meta-analyses of the randomized trials. We believe that the best evidence comes from a 2012 meta-analysis that used individual patient data from nearly 6300 patients enrolled in 11 randomized trials that compared either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -eluting or sirolimus-eluting stents (PES or SES) to bare metal stents (BMS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/20\">",
"     20",
"    </a>",
"    ]. The following findings were noted after follow-up as long as six years (mean of 3.3 years):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference in mortality, which was the primary end point of the study (8.5 versus 10.2 percent; hazard ratio [HR] 0.85, 95% CI 0.70-1.04).",
"     </li>",
"     <li>",
"      The rate of target-vessel revascularization was lower with DES (12.7 versus 20.1 percent; HR 0.57, 95% CI 0.50-0.66).",
"     </li>",
"     <li>",
"      There was no significant difference in the cumulative rate of stent thrombosis (5.8 versus 4.3 percent; HR 1.13, 95% CI 0.86-1.47). However, the rate of very late sent thrombosis (events after two years) was higher for DES (HR 2.81, 95% CI 1.28-6.19).",
"     </li>",
"     <li>",
"      There was no significant difference in the cumulative rate of reinfarction (9.4 versus 5.9 percent; HR 1.12, 95% CI 0.88-1.41). However, after two years the rate significantly increased for DES (HR 2.06, 95% CI 1.22-3.49).",
"      <br/>",
"      <br/>",
"      This finding of a higher rate of very late stent thrombosis after DES was confirmed in a second meta-analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limitations of this meta-analysis include lack of applicability to patients who receive later generation stents (such as everolimus-, zotarolimus-, and biolimus-eluting stents) and possible lack of applicability to sicker real world patients, who were not included in the randomized trials. Longer-term outcomes comparing DES to BMS are available from the following analyses of studies that included real-world patients. The following are representative examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At three years, the cumulative mortality, rate of target vessel revascularization, and combined cumulative incidence of major adverse cardiac events (death, MI, or target vessel revascularization) were not significantly different among 505 patients who received BMS, PES, or SES in the RESEARCH and T-SEARCH registries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/22\">",
"       22",
"      </a>",
"      ]. This finding may reflect small sample size, since there were strong trends toward lower rates of target vessel revascularization with SES and PES (8.0 and 7.7 percent versus 12 percent with BMS).",
"     </li>",
"     <li>",
"      The largest analysis to evaluate the single endpoint of death in STEMI patients who received either DES or BMS comes from the state of Massachusetts mandated database of PCI procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/23\">",
"       23",
"      </a>",
"      ]. In 1298 propensity",
"      <strong>",
"       -",
"      </strong>",
"      matched pairs, the two-year risk of death was significantly lower in patients who received a DES (8.5 versus 11.6 percent). There was no significant difference in the rate of recurrent MI. However, these data should be interpreted with caution due to the possibility that unmeasured confounding affected the outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H626162737\">",
"    <span class=\"h3\">",
"     Second generation DES compared to BMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized trials, COMFORTABLE AMI and EXAMINATION, have compared second generation stents to BMS in patients with STEMI.",
"   </p>",
"   <p>",
"    The COMFORTABLE AMI trial randomly assigned 1161 patients to either biolimus-eluting or BMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/24\">",
"     24",
"    </a>",
"    ]. The biolimus on this stent was embedded in a biodegradable polymer. The primary end point was the composite rate of cardiac death, target vessel-related reinfarction, and ischemia-driven target-lesion revascularization at one year. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary end point occurred less frequently in patients receiving the biolimus-eluting stent (4.3 versus 8.7 percent; hazard ratio [HR] 0.49, 95 % CI 0.30-0.80).",
"     </li>",
"     <li>",
"      The difference in the primary end point was driven primarily by a lower risk of target vessel-related reinfarction (0.5 versus 2.7 percent) and ischemia-driven target-lesion revascularization (1.6 versus 5.7 percent).",
"     </li>",
"     <li>",
"      There was a lower rate of definite stent thrombosis with the biolimus-eluting stent (0.9 versus 2.1 percent) but the difference was not statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lower rates of stent thrombosis and target vessel-related reinfarction in patients with STEMI are similar to the findings in patients with predominantly stable disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34773?source=see_link&amp;anchor=H103379877#H103379877\">",
"     \"Coronary artery stent types in development\", section on 'Bioresorbable polymer DES'",
"    </a>",
"    .) The biolimus-eluting stent is not approved for use in the United States, but is approved for use in Europe.",
"   </p>",
"   <p>",
"    The EXAMINATION trial randomly assigned 1498 patients to receive an everolimus-eluting stent (EES) or a BMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/25\">",
"     25",
"    </a>",
"    ]. The primary combined end point included all-cause death, any recurrent MI, and any revascularization at one year. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary end point was similar in both groups (11.9 versus 14.2 percent, respectively).",
"     </li>",
"     <li>",
"      At up to three years, the rates of target vessel revascularization and definite stent thrombosis were significantly lower in the EES group (3.7 versus 6.8 and 0.5 versus 1.9 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The findings in the COMFORTABLE AMI and EXAMINATION trials establish the superiority of second generation DES to BMS with regard to target vessel revascularization. While more data, including longer follow-up, are needed to confirm the finding of a lower rate of stent thrombosis, this finding is reassuring. We believe that second generation DES are a reasonable choice for patients treated with primary PCI who are able to comply with recommendations for at least one year of dual antiplatelet therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H692166406\">",
"    <span class=\"h3\">",
"     Drug-eluting balloon plus BMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to concerns of an increase in the rate of very late stent thrombosis with DES (see",
"    <a class=\"local\" href=\"#H626162715\">",
"     'First generation DES compared to BMS'",
"    </a>",
"    above), the efficacy and safety of a drug-eluting balloon (DEB) used in conjunction with a BMS was evaluated in the DEB-AMI trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/26\">",
"     26",
"    </a>",
"    ]. In this study, 150 STEMI patients were randomly assigned to BMS, DEB (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ) plus BMS, or DES (paclitaxel). The primary end point of six-month angiographic in-stent late-luminal loss was not significantly different between the DEB-BMS and BMS groups and neither group performed as well as the DES group. In addition, DEB induced more uncovered and malapposed stent struts than BMS, but less than DES. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=see_link&amp;anchor=H18#H18\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Incomplete stent apposition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24756055\">",
"    <span class=\"h2\">",
"     Extent of revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary PCI should be limited to the infarct-related artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Some experts have suggested that patients with severe multivessel disease and persistent shock after PCI of the infarct-related vessel may benefit from same-procedure catheter-based revascularization (or bypass surgery) of noninfarct-related arteries. This hypothesis was not substantiated in a review of over 3000 patients with cardiogenic shock treated with primary PCI in the National (US) Cardiovascular Data Registry (NCDR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/29\">",
"     29",
"    </a>",
"    ]. Those receiving multivessel PCI had greater in-hospital mortality (36.5 versus 27.8 percent; adjusted odds ratio 1.54, 95% CI 1.22-1.95) compared to those treated with infarct-related artery PCI only. These results should be interpreted with caution given the observational nature of the data and potential for unmeasured confounding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1365940\">",
"    <span class=\"h2\">",
"     Intraaortic balloon counterpulsation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who undergo primary PCI and receive aggressive antithrombotic therapy, we do not use an intraaortic balloon pump (IABP) for those without cardiac shock, acute mitral regurgitation, or acute ventricular septal rupture.",
"   </p>",
"   <p>",
"    Studies, performed before the routine use of stenting and aggressive antithrombotic therapy, came to differing conclusions regarding the benefit from prophylactic IABP",
"    <strong>",
"     after",
"    </strong>",
"    primary PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One observational study suggested benefit from the use of prophylactic IABP",
"    <strong>",
"     before",
"    </strong>",
"    primary PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/32\">",
"     32",
"    </a>",
"    ]. This issue was directly addressed in the CRISP AMI trial, which randomly assigned 337 patients who presented within six hours of acute anterior STEMI but without cardiogenic shock, to either IABP or no IABP prior to primary PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/33\">",
"     33",
"    </a>",
"    ]. There was no significant difference in the primary outcome of mean infarct size (expressed as a percentage of left ventricular mass and measured by cardiac magnetic resonance imaging at 3-5 days) between the IABP and no IABP groups (42.1 and 37.5 percent respectfully). At six months there was no difference in the rate of all cause death.",
"   </p>",
"   <p>",
"    This issue is discussed elsewhere in detail. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=see_link&amp;anchor=H24#H24\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\", section on 'Intraaortic balloon pump'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1365947\">",
"    <span class=\"h2\">",
"     Ischemic postconditioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic postconditioning refers to the ability of a series of brief coronary artery occlusions after a severe ischemic insult to protect against ischemic-reperfusion injury. An initial clinical trial in primary PCI suggested smaller infarct size and a higher myocardial blush grade. Before postconditioning can be recommended in patients who undergo primary PCI, additional studies are needed to confirm efficacy in a larger number of patients, to determine the optimal protocol, to assess treatment effect using a more accepted measure of infarct size after reperfusion (eg, SPECT imaging), and to determine long-term outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39529?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical implications of ischemic preconditioning\", section on 'Ischemic postconditioning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1365954\">",
"    <span class=\"h2\">",
"     Intracoronary hyperoxemic reperfusion therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon success in the reduction of infarct size in animal models, an infusion of blood mixed with aqueous oxygen into the coronary arteries after primary PCI has been shown to be safe and feasible in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, benefit was not confirmed in the first outcome trial of this technology (AMIHOT) in which 269 patients with STEMI were randomly assigned after successful primary or rescue PCI to receive intracoronary hyperoxemic reperfusion or normoxemic blood autoreperfusion over 90 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/35\">",
"     35",
"    </a>",
"    ]. There was no difference between the two groups in any of the primary efficacy endpoints (final infarct size at 14 days, ST-segment resolution, or change in regional wall motion score index at three months). At 30 days, the incidence of major adverse cardiac events was not different between the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1365961\">",
"    <span class=\"h2\">",
"     Thrombectomy devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of thrombectomy in patients with STEMI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=see_link&amp;anchor=H9#H9\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\", section on 'Thrombectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24756062\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive therapy with primary PCI primarily consists of antiplatelet and antithrombotic therapy to reduce thrombotic complications and beta blockers. Other nonpharmacologic adjunctive therapies will be discussed here as well.",
"   </p>",
"   <p>",
"    The role of intracoronary agents during PCI to prevent no reflow is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=see_link&amp;anchor=H8#H8\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24756069\">",
"    <span class=\"h2\">",
"     Antithrombotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role and duration of antiplatelet and anticoagulant therapy in patients undergoing primary PCI are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link&amp;anchor=H14#H14\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Primary PCI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, we recommend the following approach, which is in general agreement with the 2013 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association STEMI guideline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      &mdash; Nonenteric coated aspirin is given as soon as possible after the onset of symptoms in patients thought to have an acute MI. Therapy is begun with a loading dose of 162 to 325 mg of uncoated aspirin. The first tablet should be chewed or crushed to rapidly establish a high blood level.",
"     </li>",
"     <li>",
"      A platelet P2Y12 receptor blocker is given to all patients undergoing primary PCI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       Clopidogrel",
"      </a>",
"      &mdash; We suggest a clopidogrel loading dose of 600 mg, to be given as soon as possible after presentation, followed by a maintenance dose of 75",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link&amp;anchor=H17#H17\">",
"       \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'With primary PCI'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H7#H7\">",
"       \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Timing and dose'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       Prasugrel",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      &mdash; Prasugrel and ticagrelor are newer oral antiplatelet agents that inhibit platelet aggregation more quickly than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      . We suggest a loading dose of 60 mg of prasugrel or a loading dose of 180 mg of ticagrelor to be given as soon as possible after presentation or at the time of PCI. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link&amp;anchor=H17#H17\">",
"       \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'With primary PCI'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor &mdash; Among patients with an STEMI, published trials have showed significant reductions in mortality and reinfarction with glycoprotein (GP)",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor therapy prior to primary PCI. Early administration of thienopyridine derivatives may attenuate this benefit. The role of GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor therapy, either early after the diagnosis of STEMI is made or later in the catheterization laboratory during primary PCI, is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link&amp;anchor=H24#H24\">",
"       \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Glycoprotein IIb/IIIa inhibitors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anticoagulant therapy &mdash; Patients undergoing primary PCI typically receive intravenous unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH) during the procedure to prevent acute vessel closure due to thrombosis. Heparin monitoring is usually performed via serial monitoring of the activated clotting time (ACT). Careful monitoring of the ACT is important because some patients have persistent thrombin activity despite heparin therapy.",
"   </p>",
"   <p>",
"    <br/>",
"    A target ACT of 250 to 350 seconds seems to be most often used in interventional practice. However, the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    regimen should probably be less aggressive (target ACT 200 to 250 seconds) when GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors are used. Careful monitoring of the ACT is important because some patients have persistent thrombin activity despite heparin therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link&amp;anchor=H8#H8\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Unfractionated heparin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H19#H19\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Heparin'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Postprocedural heparin is",
"    <strong>",
"     not recommended",
"    </strong>",
"    in patients with an uncomplicated procedure, since it is associated with increased bleeding and vascular complications without added benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/36\">",
"     36",
"    </a>",
"    ]. Sheath removal should be accomplished when the ACT falls to less than 150 to 180 seconds to reduce the incidence of complications at the access site.",
"    <br/>",
"    <br/>",
"    The potential use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    in patients with STEMI undergoing PCI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link&amp;anchor=H14#H14\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Primary PCI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24756076\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers significantly reduce morbidity and mortality in patients with an acute MI. They are also beneficial in patients undergoing primary PCI, and probably should be administered intravenously (in hemodynamically stable patients) before PCI as well as orally after the procedure, unless a contraindication is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/53/11098?source=see_link\">",
"     \"Beta blockers in the management of acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A possible benefit from preprocedural intravenous administration of a beta blocker was shown in a retrospective analysis from the CADILLAC trial of 2082 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/38\">",
"     38",
"    </a>",
"    ]. At 30 days, patients who had received a preprocedural beta blocker had a significantly lower mortality than those who had not (1.5 versus 2.8 percent); the reduction in mortality was limited to patients who had not been receiving an oral beta blocker before admission. Although preprocedural use is preferred, lower mortality has also been seen in retrospective analyses when beta blocker therapy is begun after primary PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1365711\">",
"    <span class=\"h1\">",
"     CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;If coronary artery bypass surgery is necessary, mortality is increased in the first three to seven days after the infarction. This risk must be weighed against the estimated benefit from early surgery; surgery should be delayed in patients who are stable but should be performed during the initial hospitalization in those with critical anatomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6505?source=see_link\">",
"     \"Coronary artery bypass graft surgery after acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24756125\">",
"    <span class=\"h1\">",
"     EARLY DISCHARGE IN LOW-RISK PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study which used the Zwolle risk index, more than two-thirds of patients undergoing primary PCI were classified as low risk (risk score &le;3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35658?source=see_link&amp;anchor=H7#H7\">",
"     \"Risk stratification for cardiac events after acute ST elevation myocardial infarction\", section on 'Zwolle primary PCI index'",
"    </a>",
"    .) For these patients, the mortality rate was 0.1 percent at two days and 0.2 percent between 2 and 10 days post-MI. It was suggested that such low-risk patients could safely be discharged early (48 hours after PCI).",
"   </p>",
"   <p>",
"    The potential safety of early discharge was evaluated in the PAMI-2 trial, which included 471 patients who were deemed to be at low risk after successful primary PCI (age &le;70, no malignant arrhythmias, native vessel being the infarct-related artery, one or two vessel disease, and LVEF &gt;45 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31721/abstract/42\">",
"     42",
"    </a>",
"    ]. These patients were randomly assigned to traditional care or to accelerated care on a telemetry unit followed by hospital discharge on day three. Patients receiving accelerated care were discharged three days earlier (4.2 versus 7.1 days for traditional care) with a significant reduction in cost. At six months, there was no significant difference between the two groups in terms of mortality (0.8 versus 0.4 percent), unstable angina, reinfarction, stroke, heart failure, or their combined occurrence (15.2 versus 17.5 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24756139\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pretreatment with fibrinolysis is limited to patients in whom primary PCI is likely to be excessively delayed because of local logistic problems or interhospital transfer. Fibrinolytic therapy given just before planned PCI (previously call facilitated PCI) is not recommended because outcomes may be worse. (See",
"      <a class=\"local\" href=\"#H1366171\">",
"       'PCI after fibrinolytic therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/42/34473?source=see_link\">",
"       \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients undergoing primary PCI, we prefer the radial, as opposed to the femoral, approach if performed by operators skilled in radial technique and if the anticipated impact on door-to-balloon time is negligible.&nbsp;",
"     </li>",
"     <li>",
"      Primary percutaneous coronary intervention (PPCI) should be limited to the infarct-related artery. (See",
"      <a class=\"local\" href=\"#H24756055\">",
"       'Extent of revascularization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Direct stenting after aspiration thrombectomy should be performed in most patients. (See",
"      <a class=\"local\" href=\"#H24756041\">",
"       'Direct stenting'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1365961\">",
"       'Thrombectomy devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are likely to comply with one year of dual antiplatelet therapy, either drug-eluting or bare-metal stents are a reasonable choice. (See",
"      <a class=\"local\" href=\"#H24756048\">",
"       'Selection of stent type'",
"      </a>",
"      above.) We prefer second to first generation drug-eluting stents.",
"     </li>",
"     <li>",
"      Insertion of an IABP should be considered in high-risk patients with hemodynamic instability or cardiogenic shock. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=see_link\">",
"       \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      All patients should receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (initial dose 162 to 325 mg followed by 75 to 162 mg once a day; the first tablet should be chewed or crushed). (See",
"      <a class=\"local\" href=\"#H24756069\">",
"       'Antithrombotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      (60 mg) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (600 mg) should be given as early as possible. (See",
"      <a class=\"local\" href=\"#H24756069\">",
"       'Antithrombotic therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link&amp;anchor=H13#H13\">",
"       \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'P2Y12 receptor blockers'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravenous therapy with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      should be given as soon as possible after presentation. (See",
"      <a class=\"local\" href=\"#H24756069\">",
"       'Antithrombotic therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link&amp;anchor=H37#H37\">",
"       \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beta blockers reduce mortality in patients undergoing primary PCI, and should be administered intravenously (in hemodynamically stable patients)",
"      <strong>",
"       before",
"      </strong>",
"      PCI as well as orally after the procedure. (See",
"      <a class=\"local\" href=\"#H24756076\">",
"       'Beta blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Discharge at 72 hours is suggested for stable patients. (See",
"      <a class=\"local\" href=\"#H24756125\">",
"       'Early discharge in low-risk patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/1\">",
"      Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 2007; 49:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/2\">",
"      Hamon M, Rasmussen LH, Manoukian SV, et al. Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial. EuroIntervention 2009; 5:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/3\">",
"      Cantor WJ, Puley G, Natarajan MK, et al. Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in acute myocardial infarction--the RADIAL-AMI pilot randomized trial. Am Heart J 2005; 150:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/4\">",
"      Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 2011; 377:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/5\">",
"      Mehta SR, Jolly SS, Cairns J, et al. Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. J Am Coll Cardiol 2012; 60:2490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/6\">",
"      Romagnoli E, Biondi-Zoccai G, Sciahbasi A, et al. Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. J Am Coll Cardiol 2012; 60:2481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/7\">",
"      Valgimigli M, Saia F, Guastaroba P, et al. Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell'Emilia-Romagna) multicenter registry. JACC Cardiovasc Interv 2012; 5:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/8\">",
"      Baklanov DV, Kaltenbach LA, Marso SP, et al. The prevalence and outcomes of transradial percutaneous coronary intervention for ST-segment elevation myocardial infarction: analysis from the National Cardiovascular Data Registry (2007 to 2011). J Am Coll Cardiol 2013; 61:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/9\">",
"      Loubeyre C, Morice MC, Lef&egrave;vre T, et al. A randomized comparison of direct stenting with conventional stent implantation in selected patients with acute myocardial infarction. J Am Coll Cardiol 2002; 39:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/10\">",
"      Ly HQ, Kirtane AJ, Buros J, et al. Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. Am J Cardiol 2005; 95:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/11\">",
"      Antoniucci D, Valenti R, Migliorini A, et al. Direct infarct artery stenting without predilation and no-reflow in patients with acute myocardial infarction. Am Heart J 2001; 142:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/12\">",
"      M&ouml;ckel M, Vollert J, Lansky AJ, et al. Comparison of direct stenting with conventional stent implantation in acute myocardial infarction. Am J Cardiol 2011; 108:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/13\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:e574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/14\">",
"      Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/15\">",
"      Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006; 355:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/16\">",
"      Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005; 293:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/17\">",
"      Menichelli M, Parma A, Pucci E, et al. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol 2007; 49:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/18\">",
"      Kelbaek H, Thuesen L, Helqvist S, et al. Drug-eluting versus bare metal stents in patients with st-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation 2008; 118:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/19\">",
"      Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009; 360:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/20\">",
"      De Luca G, Dirksen MT, Spaulding C, et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med 2012; 172:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/21\">",
"      Kalesan B, Pilgrim T, Heinimann K, et al. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012; 33:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/22\">",
"      Daemen J, Tanimoto S, Garc&iacute;a-Garc&iacute;a HM, et al. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol 2007; 99:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/23\">",
"      Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 2008; 359:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/24\">",
"      R&auml;ber L, Kelb&aelig;k H, Ostojic M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012; 308:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/25\">",
"      Sabate M, Cequier A, I&ntilde;iguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012; 380:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/26\">",
"      Belkacemi A, Agostoni P, Nathoe HM, et al. First results of the DEB-AMI (drug eluting balloon in acute ST-segment elevation myocardial infarction) trial: a multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes. J Am Coll Cardiol 2012; 59:2327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/27\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/28\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/29\">",
"      Cavender MA, Milford-Beland S, Roe MT, et al. Prevalence, predictors, and in-hospital outcomes of non-infarct artery intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (from the National Cardiovascular Data Registry). Am J Cardiol 2009; 104:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/30\">",
"      Ohman EM, George BS, White CJ, et al. Use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction. Results of a randomized trial. The Randomized IABP Study Group. Circulation 1994; 90:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/31\">",
"      Stone GW, Marsalese D, Brodie BR, et al. A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. Second Primary Angioplasty in Myocardial Infarction (PAMI-II) Trial Investigators. J Am Coll Cardiol 1997; 29:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/32\">",
"      Brodie BR, Stuckey TD, Hansen C, Muncy D. Intra-aortic balloon counterpulsation before primary percutaneous transluminal coronary angioplasty reduces catheterization laboratory events in high-risk patients with acute myocardial infarction. Am J Cardiol 1999; 84:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/33\">",
"      Patel MR, Smalling RW, Thiele H, et al. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. JAMA 2011; 306:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/34\">",
"      Dixon SR, Bartorelli AL, Marcovitz PA, et al. Initial experience with hyperoxemic reperfusion after primary angioplasty for acute myocardial infarction: results of a pilot study utilizing intracoronary aqueous oxygen therapy. J Am Coll Cardiol 2002; 39:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/35\">",
"      O'Neill WW, Martin JL, Dixon SR, et al. Acute Myocardial Infarction with Hyperoxemic Therapy (AMIHOT): a prospective, randomized trial of intracoronary hyperoxemic reperfusion after percutaneous coronary intervention. J Am Coll Cardiol 2007; 50:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/36\">",
"      Goodman SG, Menon V, Cannon CP, et al. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:708S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/37\">",
"      Faxon DP. Beta-blocker therapy and primary angioplasty: what is the controversy? J Am Coll Cardiol 2004; 43:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/38\">",
"      Halkin A, Grines CL, Cox DA, et al. Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. J Am Coll Cardiol 2004; 43:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/39\">",
"      Kernis SJ, Harjai KJ, Stone GW, et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol 2004; 43:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/40\">",
"      Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/41\">",
"      De Luca G, Suryapranata H, van 't Hof AW, et al. Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge. Circulation 2004; 109:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31721/abstract/42\">",
"      Grines CL, Marsalese DL, Brodie B, et al. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. PAMI-II Investigators. Primary Angioplasty in Myocardial Infarction. J Am Coll Cardiol 1998; 31:967.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15358 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_62_31721=[""].join("\n");
var outline_f30_62_31721=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24756139\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24755908\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1366171\">",
"      PCI AFTER FIBRINOLYTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1365622\">",
"      TECHNICAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32226860\">",
"      Radial versus femoral approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24756041\">",
"      Direct stenting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24756048\">",
"      Selection of stent type",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H626162715\">",
"      - First generation DES compared to BMS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H626162737\">",
"      - Second generation DES compared to BMS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H692166406\">",
"      - Drug-eluting balloon plus BMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24756055\">",
"      Extent of revascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1365940\">",
"      Intraaortic balloon counterpulsation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1365947\">",
"      Ischemic postconditioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1365954\">",
"      Intracoronary hyperoxemic reperfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1365961\">",
"      Thrombectomy devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24756062\">",
"      ADJUNCTIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24756069\">",
"      Antithrombotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24756076\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1365711\">",
"      CABG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24756125\">",
"      EARLY DISCHARGE IN LOW-RISK PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24756139\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=related_link\">",
"      Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39529?source=related_link\">",
"      Clinical implications of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/62/16360?source=related_link\">",
"      Comparison of drug-eluting intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6505?source=related_link\">",
"      Coronary artery bypass graft surgery after acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34773?source=related_link\">",
"      Coronary artery stent types in development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1081?source=related_link\">",
"      Drug-eluting compared to bare metal intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43702?source=related_link\">",
"      Drug-eluting intracoronary stents: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24889?source=related_link\">",
"      General principles of the use of intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8634?source=related_link\">",
"      Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/42/34473?source=related_link\">",
"      Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29961?source=related_link\">",
"      Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35658?source=related_link\">",
"      Risk stratification for cardiac events after acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/31/37369?source=related_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=related_link\">",
"      Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_62_31722="Uncomplicated gallstone disease in adults";
var content_f30_62_31722=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Uncomplicated gallstone disease in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/62/31722/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/62/31722/contributors\">",
"     Salam F Zakko, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/62/31722/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/62/31722/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/62/31722/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/62/31722/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/62/31722/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallstones are common, particularly in Western populations (",
"    <a class=\"graphic graphic_table graphicRef57092 \" href=\"mobipreview.htm?0/50/814\">",
"     table 1",
"    </a>",
"    ). In the United States, gallstones are seen in approximately 6 percent of men and 9 percent of women. Most individuals with gallstones are asymptomatic throughout their lives. When the stones start causing symptoms, the condition is referred to as gallstone disease. Uncomplicated gallstone disease refers to stones in the gallbladder that are associated with biliary colic in the absence of complications, such as acute cholecystitis, cholangitis, or gallstone pancreatitis.",
"   </p>",
"   <p>",
"    Determining whether a patient's upper digestive symptoms are the result of gallstones detected on imaging can be challenging. While both gallstones and upper digestive symptoms are common in the general population, they are not always related. Differentiating patients with uncomplicated gallstone disease from those with other disorders and an incidental finding of gallstones is important, since cholecystectomy is often curative in those with symptomatic gallstones, but it exposes those with incidental gallstones to unnecessary risk, delays appropriate treatment for the actual cause of symptoms, and incurs unnecessary expense.",
"   </p>",
"   <p>",
"    This topic will review uncomplicated gallstone disease. The epidemiology of and risk factors for gallstones, the approach to patients with an incidental finding of gallstones, gallstone disease in pregnant women, and the complications of gallstone disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4489?source=see_link\">",
"     \"Epidemiology of and risk factors for gallstones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10374?source=see_link\">",
"     \"Approach to the patient with incidental gallstones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28201?source=see_link\">",
"     \"Gallstone disease in pregnant women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14297?source=see_link&amp;anchor=H3#H3\">",
"     \"Etiology of acute pancreatitis\", section on 'Gallstones'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24790?source=see_link\">",
"     \"Acute cholangitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40936?source=see_link\">",
"     \"Approach to the patient with suspected choledocholithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73972061\">",
"    <span class=\"h1\">",
"     CATEGORIZATION OF PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When considering gallstone disease, we have found it helpful to categorize patients into the following clinical groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Category 1: Gallstones on imaging studies but without symptoms (incidental gallstones)",
"     </li>",
"     <li>",
"      Category 2: Typical biliary symptoms and gallstones on imaging studies with no evidence of complications (uncomplicated gallstone disease)",
"     </li>",
"     <li>",
"      Category 3: Atypical symptoms and gallstones on imaging studies",
"     </li>",
"     <li>",
"      Category 4: Typical biliary symptoms but without gallstones on ultrasound",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As will be discussed below, the approach to patients in categories 1 and 2 is generally straightforward. Patients in category 1 should generally be left alone, while those in category 2 should undergo treatment aimed at eliminating the gallstones. By contrast, optimal approaches to patients who fall into the last two categories (3 and 4) are less clear. Management of such patients should be individualized and depends largely upon the likelihood (based upon clinical features and diagnostic testing) that the patient's symptoms are related to the gallstones. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H243183886\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with gallstones are asymptomatic. Of those with incidental (asymptomatic) gallstones, approximately 20 percent will develop symptoms over 15 years of follow-up, but their initial symptoms are typically not severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10374?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the patient with incidental gallstones\", section on 'Natural history of asymptomatic gallstones'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with symptoms the natural history is variable, ranging from symptom resolution to the development of severe complications. This was demonstrated in a study that included 94 patients with mild symptoms and 119 patients with severe symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/2\">",
"     2",
"    </a>",
"    ]. The patients were followed for a mean of 8.7 years. At the end of follow-up, 58 percent of the patients with mild symptoms were asymptomatic, 17 percent had mild symptoms, and 25 percent had severe symptoms. On the other hand, 52 percent of those with severe symptoms were asymptomatic, 17 percent had mild symptoms, and 31 percent had severe symptoms.",
"   </p>",
"   <p>",
"    Complications that may develop in patients with gallstones include acute cholecystitis, choledocholithiasis with or without acute cholangitis, and gallstone pancreatitis. Acute cholecystitis is the most common complication. In a systematic review, it was seen in 6 to 11 percent of patients with symptomatic gallstones over a median followup of 7 to 11 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/3\">",
"     3",
"    </a>",
"    ]. Rare complications include gallbladder cancer, gallstone ileus, and Mirizzi syndrome.",
"   </p>",
"   <p>",
"    Patients with asymptomatic gallstones appear to have a slightly lower risk of complications than those with symptomatic gallstones. This was demonstrated in a study that followed 123 patients with asymptomatic gallstones and 298 patients with mild symptoms due to gallstones for up to 25 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/4\">",
"     4",
"    </a>",
"    ]. It found that the cumulative probability of developing severe complications was lower among patients with asymptomatic gallstones compared with those with mild symptoms after 5, 10, 15, and 20 years of follow-up (4 versus 5 percent, 5 versus 12 percent, 10 versus 15 percent, and 16 versus 18 percent, respectively; p = 0.03).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with uncomplicated gallstone disease typically present with biliary colic, normal physical examination findings, and normal laboratory test results. Patients often report associated diaphoresis, nausea, and vomiting.",
"   </p>",
"   <p>",
"    While patients may present with atypical symptoms, such as chest pain or nonspecific abdominal discomfort, the absence of biliary colic should prompt an investigation for alternative diagnoses. On the other hand, biliary colic that is associated with fevers, jaundice, or abnormal blood tests (leukocytosis, liver tests, pancreas tests) suggests the development of a complication of gallstone disease. (See",
"    <a class=\"local\" href=\"#H58360586\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8995491\">",
"    <span class=\"h2\">",
"     Biliary colic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the name, the pain of biliary colic is usually constant and not colicky. The classic description is of an intense, dull discomfort located in the right upper quadrant, epigastrium, or (less often) substernal area that may radiate to the back (particularly the right shoulder blade) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The pain is often associated with diaphoresis, nausea, and vomiting. It is not exacerbated by movement and is not relieved by squatting, bowel movements, or passage of flatus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biliary colic is usually caused by the gallbladder contracting in response to hormonal or neural stimulation, forcing a stone (or possibly sludge) against the gallbladder outlet or cystic duct opening, leading to increased intra-gallbladder pressure. This increase in pressure then results in pain. Eating a fatty meal is a common trigger for gallbladder contraction, and many patients report postprandial pain. However, an association with meals is not universal, and in a significant proportion of patients the pain is nocturnal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pain typically lasts at least 30 minutes, plateauing within an hour. As the gallbladder relaxes, the stones often fall back from the cystic duct and the pain slowly subsides, with an entire attack usually lasting less than six hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/5\">",
"     5",
"    </a>",
"    ]. In many patients, the pain is not severe, which is why patients often have had several attacks before seeking medical attention. The frequency of recurrent attacks is variable, ranging from hours to years, though most patients do not have symptoms on a daily basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/7\">",
"     7",
"    </a>",
"    ]. Typically, the pain has a characteristic pattern and timing for an individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22973364\">",
"    <span class=\"h2\">",
"     Atypical symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous symptoms other than biliary colic have been reported in patients with gallstones, but their predictive value for the presence of gallstone disease is poor. In many cases they may coexist with biliary colic but may or may not be related to the gallstones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Atypical symptoms seen in patients with gallstones include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Nonspecific abdominal pain",
"     </li>",
"     <li>",
"      Belching",
"     </li>",
"     <li>",
"      Fullness after",
"      <span class=\"nowrap\">",
"       meals/early",
"      </span>",
"      satiety",
"     </li>",
"     <li>",
"      Fluid regurgitation",
"     </li>",
"     <li>",
"      Abdominal",
"      <span class=\"nowrap\">",
"       distension/bloating",
"      </span>",
"     </li>",
"     <li>",
"      Epigastric or retrosternal burning",
"     </li>",
"     <li>",
"      Nausea or vomiting without biliary colic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether atypical symptoms are due to the gallstones or due to a coexistent problem can be difficult to determine. Patients with atypical symptoms without associated biliary colic should be evaluated for alternative diagnoses, even if gallstones are demonstrated on imaging. (See",
"    <a class=\"local\" href=\"#H58360586\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8995514\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with biliary colic due to uncomplicated gallstone disease are usually not ill appearing and do not have fever or tachycardia. The pain is often not severe enough to bring the patient to the emergency department. If a patient does present during a pain episode, the abdominal examination is generally benign. Biliary colic is visceral pain and there are no peritoneal signs because the gallbladder is not inflamed. However, voluntary guarding may be encountered depending upon the severity of the pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8995574\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory studies should be normal in patients with uncomplicated gallstone disease, both during asymptomatic periods and during attacks of pain. Abnormal blood tests (leukocytosis, elevated liver or pancreas tests) suggest the development of a complication of gallstone disease, such as cholecystitis, cholangitis, or pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24790?source=see_link\">",
"     \"Acute cholangitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58365548\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with uncomplicated gallstone disease will have gallstones demonstrated on transabdominal ultrasound. Other imaging studies, such as plain abdominal x-rays or computed tomography (CT) scanning of the abdomen are less sensitive than ultrasound, though patients may have had the tests as part of the general evaluation of their abdominal pain. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Transabdominal ultrasound'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Plain abdominal x-rays rarely reveal gallstones because only about 10 percent of gallstones contain enough calcium to make them sufficiently radio-opaque to be visible on a plain radiograph (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71203 \" href=\"mobipreview.htm?7/14/7407\">",
"     image 1",
"    </a>",
"    ). The sensitivity of CT scan for gallstones has been reported to be 55 to 80 percent. Gallstones may be missed on CT because many stones are isodense with bile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of uncomplicated gallstone disease should be suspected in a patient with biliary colic, a normal physical examination, and normal laboratory tests (complete blood count, aminotransferases, bilirubin, alkaline phosphatase, amylase, and lipase). Such patients should undergo an imaging study to determine if there are gallbladder stones or sludge. Typically, the evaluation begins with a transabdominal ultrasound since it is the most sensitive modality for detecting gallbladder stones. If the transabdominal ultrasound is negative in a patient with biliary colic, additional studies that may help with the diagnosis include endoscopic ultrasound (EUS) and bile microscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Transabdominal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transabdominal ultrasound is generally considered to be the most useful test to detect the presence of gallstones since it is non-invasive, readily available, relatively inexpensive, and does not subject the patient to ionizing radiation. The examination should be conducted with the patient having fasted for at least eight hours, because stones are best seen when surrounded by bile in a distended gallbladder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58361345\">",
"    <span class=\"h3\">",
"     Characteristics of stones on ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with uncomplicated gallstone disease may have ultrasound findings of gallstones, gravel, or sludge. Distinguishing among these three entities is generally not clinically important because they are managed identically. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    On ultrasound, gallstones appear as echogenic foci that cast an acoustic shadow (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70175 \" href=\"mobipreview.htm?41/14/42211\">",
"     image 2",
"    </a>",
"    ) and seek gravitational dependency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Gravel is the appearance of multiple small stones that are echogenic and cast shadows. Sludge is echogenic in appearance but does not cast an acoustic shadow. It is also more viscous and does not move to the dependent portion of the gallbladder as rapidly as gravel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sludge seen on ultrasound represents microlithiasis (lithogenic bile that contains cholesterol monohydrate crystals, bilirubin granules, and a mucus glycoprotein gel) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Microlithiasis can produce biliary colic and lead to complications such as acute cholangitis and acute pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. It may also progress to macroscopic gallstones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    False negative results may be obtained if the gallbladder is completely filled with stones or if it is contracted around many stones. In such cases, the findings may be confused with gas in a partially collapsed duodenal bulb, emphysematous cholecystitis, porcelain gallbladder, or a calcified hepatic artery aneurysm. False positive results may be seen if gallbladder polyps are present, since they produce sonographic images similar to those seen with gallstones, though they do not cast an acoustic shadow (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70175 \" href=\"mobipreview.htm?41/14/42211\">",
"     image 2",
"    </a>",
"    ). The ultrasonographer performing the procedure regularly uses specific maneuvers and techniques to identify and distinguish gallstones from some of these other entities. As a result, ultrasonography is highly operator-dependent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13209?source=see_link\">",
"     \"Gallbladder polyps and cholesterolosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58360944\">",
"    <span class=\"h3\">",
"     Test characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have evaluated the ability of transabdominal ultrasound to detect gallstones, though it is important to recognize that precise estimates of sensitivity and specificity are difficult to determine since surgical confirmation of a negative sonogram is unlikely.",
"   </p>",
"   <p>",
"    A systematic review estimated that the sensitivity was 84 percent (95% confidence interval [CI] 76 to 99%) and specificity was 99 percent (95% CI 97 to 100%) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/28\">",
"     28",
"    </a>",
"    ]. Rarely, advanced scarring and contraction of the gallbladder around gallstones leads to nonvisualization of the gallbladder lumen, which has a specificity of 96 percent, but it should also raise the possibility of gallbladder cancer.",
"   </p>",
"   <p>",
"    When compared with other cross-sectional imaging modalities and cholecystography, ultrasound has the highest sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Modern sonographic equipment is able to detect stones as small as 1.5 to 2 mm in diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/29\">",
"     29",
"    </a>",
"    ]. Smaller stones may be missed, and the sensitivity falls to 50 to 60 percent for stones less than 3 mm in diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The accuracy of transabdominal ultrasonography is operator dependent. The entire gallbladder must be examined axially and sagittally. Every effort should be made to examine the outlet of the gallbladder (Hartmann's pouch), where gallstones may be difficult to detect. The gallbladder neck must be traced all the way into the porta hepatis to exclude stones in this region. If an out-pouching from the gallbladder (Phrygian cap) is present, the redundant portion of the fundus must not be overlooked.",
"   </p>",
"   <p>",
"    Even with an experienced operator, it is difficult to determine the number or size of stones in the gallbladder with transabdominal ultrasound. This is especially true for very small stones (1 or 2 mm in diameter) that frequently, when present in large numbers, can appear on transabdominal ultrasound as one large stone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150685460\">",
"    <span class=\"h2\">",
"     Next steps if the ultrasound is negative",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with symptoms that do not fit the classic description for biliary colic, an evaluation for non-biliary causes for the patient's symptoms should be pursued. However, in a patient with classic biliary colic, if the initial transabdominal ultrasound was negative, additional testing to detect missed gallstones, sludge, or microlithiasis is indicated. (See",
"    <a class=\"local\" href=\"#H58360586\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65536788\">",
"    <span class=\"h3\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with typical biliary colic but no gallstones on ultrasonography, we usually repeat the transabdominal ultrasound in a few weeks. If the repeat transabdominal ultrasound is negative, the patient may have microlithiasis or may be a category 4 patient (typical biliary symptoms without gallstones on ultrasound). In such patients the next step is debatable. The approach depends on the patient's preferences, age, and risk factors for adverse outcomes with invasive procedures.",
"   </p>",
"   <p>",
"    The more definitive approach is to proceed with endoscopic ultrasonography (EUS) to look for missed stones or sludge and, if the EUS is negative, obtain samples of bile for bile microscopy to evaluate for microlithiasis. However, some centers recommend cholecystokinin-stimulated cholescintigraphy before an EUS with bile sampling. Cholescintigraphy is more widely available and less invasive. A positive result (low gallbladder ejection fraction) suggests functional gallbladder disorder, though it may also be seen in the setting of microlithiasis or sludge and microcrystals that are interfering with bile ejection through the cystic duct. Differentiating between the two entities is typically not required since both conditions are treated with cholecystectomy. If the cholescintigraphy is normal, EUS can then be pursued. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8200?source=see_link&amp;anchor=H366143604#H366143604\">",
"     \"Functional gallbladder disorder in adults\", section on 'CCK-stimulated cholescintigraphy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If medical dissolution therapy with oral bile acids is being considered, EUS with bile collection for microscopy should be done first to confirm the presence of microlithiasis or sludge. Many patients with microlithiasis will respond to a one- to two-year course of oral bile acid therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6408?source=see_link&amp;anchor=H4#H4\">",
"     \"Dissolution therapy for the treatment of gallstones\", section on 'Bile acid therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65536795\">",
"    <span class=\"h3\">",
"     Repeat transabdominal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeating the transabdominal ultrasound increases the sensitivity for detecting stones, particularly if they are smaller than 3 mm in diameter. A repeat examination should pay particular attention to regions of the gallbladder where stones are easily overlooked [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients with a negative repeat transabdominal ultrasound may still have microlithiasis or small stones that were missed. EUS and bile microscopy may identify missed stones or microlithiasis. These tests also both include an upper endoscopy, which also helps to exclude other conditions, such as peptic ulcer disease. If no stones are seen with EUS and bile microscopy, other disorders in the differential diagnosis of biliary colic (eg, sphincter of Oddi dysfunction or functional gallbladder disorder) should be considered. (See",
"    <a class=\"local\" href=\"#H58360586\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is important to thoroughly evaluate category 4 patients who have biliary colic but negative transabdominal ultrasounds because patients with missed stones or microlithiasis will typically respond to cholecystectomy. However, patients with other diagnoses, such as sphincter of Oddi dysfunction, peptic ulcer disease, dyspepsia, or irritable bowel syndrome, may not improve or may even worsen following cholecystectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12874?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sphincter of Oddi dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22455?source=see_link\">",
"     \"Clinical manifestations and diagnosis of irritable bowel syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8200?source=see_link\">",
"     \"Functional gallbladder disorder in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58361831\">",
"    <span class=\"h3\">",
"     Endoscopic ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging of the gallbladder can be obtained by EUS. During EUS, an ultrasound transducer on the tip of an endoscope is placed into contact with the gastric antrum, which is in close proximity to the gallbladder. This permits gallbladder visualization without interference from bowel gas, subcutaneous tissue, or the liver. As a result, EUS is more sensitive than transabdominal ultrasound for the detection of gallstones, particularly in patients who are obese or have other anatomic considerations that limit gallbladder visualization with transabdominal ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have demonstrated that EUS is useful for the detection of small stones and microlithiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. In one study of 45 patients in whom there was a clinical suspicion of cholelithiasis but with at least two normal transabdominal ultrasound examinations, EUS detected evidence of cholelithiasis in 26 patients (58 percent). The sensitivity and specificity of EUS for detecting cholelithiasis were 96 and 86 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a second study of 89 patients with acute pancreatitis, EUS revealed small gallbladder stones (1 to 9 mm) in 14 of 18 patients who had otherwise negative standard imaging studies, including transabdominal ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/36\">",
"     36",
"    </a>",
"    ]. Subsequent endoscopic retrograde cholangiopancreatography (ERCP) and cholecystectomy confirmed the presence of stones in all 14 patients. None of the remaining four patients developed evidence of cholelithiasis during a median follow-up of 22 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8996071\">",
"    <span class=\"h3\">",
"     Bile microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile microscopy detects microcrystals of cholesterol or amorphous bilirubinate as indirect evidence for the presence of microlithiasis in the bile. It has an overall sensitivity of 65 to 90 percent for identifying patients with gallstones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/38-42\">",
"     38-42",
"    </a>",
"    ]. Because of the improved sensitivity of transabdominal ultrasonography for detection of small stones and sludge, there is less need for microcrystal analysis. However, it still has a role in category 4 patients with biliary colic without gallstones on transabdominal ultrasound. However, because obtaining a sample for bile microscopy during endoscopy can take over 45 minutes, we reserve the procedure for patients with a negative EUS.",
"   </p>",
"   <p>",
"    The test is based upon the theory that patients with cholesterol microlithiasis have bile that is supersaturated with cholesterol and thus have cholesterol monohydrate crystals in their gallbladder bile (",
"    <a class=\"graphic graphic_picture graphicRef73479 \" href=\"mobipreview.htm?27/35/28211\">",
"     picture 1",
"    </a>",
"    ), while those with bilirubinate microlithiasis have amorphous reddish-brown bilirubinate granules in their gallbladders (",
"    <a class=\"graphic graphic_picture graphicRef80050 \" href=\"mobipreview.htm?23/48/24325\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. However, the methods for performing the test have not been well standardized, which has led to confusion regarding how to collect and process the bile samples for analysis and what constitutes a positive test.",
"   </p>",
"   <p>",
"    The proportion of patients with suspected gallstones but negative transabdominal ultrasound found to have microlithiasis varies substantially among reports. A systematic review found that microcrystals accounted for 7 to 79 percent of cases of idiopathic pancreatitis, 83 percent of patients with unexplained biliary-type pain, and 25 to 60 percent of patients with altered biliary and pancreatic sphincter function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the presence of any cholesterol crystals is theoretically abnormal, to increase specificity, some of the newer reports presume the test to be positive only if more than three crystals are seen per high power field [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/46\">",
"     46",
"    </a>",
"    ]. However, whether findings based upon this approach correlate with clinical outcomes has not been established. As a result, this presumption has not been widely accepted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64850136\">",
"    <span class=\"h4\">",
"     Bile collection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most available studies describe the test as it pertains to the detection of microlithiasis in patients with idiopathic recurrent pancreatitis and have used variable techniques for bile collection, bile processing, and microscopic crystal analysis. Nevertheless, most investigators agree that crystals are formed in the gallbladder where bile is concentrated, so gallbladder bile rather than hepatic bile should be analyzed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/23,39,47\">",
"     23,39,47",
"    </a>",
"    ]. Hepatic bile is significantly less concentrated and thus has a lower yield for the detection of microlithiasis.",
"   </p>",
"   <p>",
"    Gallbladder bile can be collected using the following techniques:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Through direct percutaneous puncture of the gallbladder under ultrasound or fluoroscopic guidance",
"     </li>",
"     <li>",
"      During endoscopic retrograde cholangiopancreatography, either through selective gallbladder cannulation or by aspirating bile from the common bile duct after stimulating gallbladder contraction with a slow intravenous infusion of the cholecystokinin (CCK) analogue,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8435?source=see_link\">",
"       sincalide",
"      </a>",
"     </li>",
"     <li>",
"      During endoscopy by suctioning bile from the duodenum in the region of the ampulla after gallbladder stimulation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8435?source=see_link\">",
"       sincalide",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most cases, collection during endoscopy is the simplest and most practical method. Since EUS includes an endoscopic examination, bile collection can be performed during the same session as an EUS, which increases the sensitivity for detecting gallstones over that of EUS alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/35,37\">",
"     35,37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H58361831\">",
"     'Endoscopic ultrasound'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Our approach in patients with biliary colic and a negative EUS is to collect a bile sample during the same endoscopic session as the EUS.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8435?source=see_link\">",
"     Sincalide",
"    </a>",
"    (0.03",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    body weight) is given by intravenous drip over 45 minutes; the longer infusion is safer and more effective than a short bolus technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/48\">",
"     48",
"    </a>",
"    ]. The tip of the endoscope is positioned next to the ampulla and the bile is aspirated. Bile flow usually starts to accelerate within five minutes of the start of the sincalide infusion. The first 5 to 10 minutes of bile flow is normally light in color and represents common bile duct and hepatic bile. Gallbladder bile is the darker bile that starts flowing several minutes later. We use a commercially available bile collecting catheter with a mushroom tip that we introduce through the working channel of the endoscope and connect to an external suction trap. Once we start to observe dark gallbladder bile being suctioned into the collecting trap, we empty the light colored bile from the trap and begin collecting the dark bile sample. When about 10 to 20 mL of bile has been collected, we stop the Sincalide infusion and conclude the procedure. This typically takes about 30 to 45 minutes from the start of the sincalide infusion to accomplish.",
"   </p>",
"   <p>",
"    The darker bile is collected in a separate collecting tube and is incubated at 37 degrees C for 24 hours, then centrifuged at 3000 G for 30 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/49\">",
"     49",
"    </a>",
"    ]. The supernatant is discarded and the sediment is mixed into the liquid remaining at the bottom of the tube. A drop of that liquid is placed on a slide and examined using a polarizing microscope; a polarizing filter facilitates identification of cholesterol crystals, which exhibit birefringence (they shine against the dark background of the polarizing microscope). The test is considered positive if any cholesterol crystals or amorphous red-brick colored bilirubinate granules are seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8997053\">",
"    <span class=\"h2\">",
"     Tests that are rarely done",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8997156\">",
"    <span class=\"h3\">",
"     Oral cholecystography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral cholecystography can diagnose gallstones and assess gallbladder function, but it has largely been replaced by more sensitive and specific tests, such as transabdominal ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/28,50\">",
"     28,50",
"    </a>",
"    ]. It is still occasionally used in patients in whom a high quality ultrasound examination cannot be obtained (such as in obese patients), to confirm the presence of adenomyomatosis of the gallbladder, and to evaluate patients who are being considered for medical dissolution therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    , in whom it is important to demonstrate stone number and size, relative density of the stones to bile, cystic duct patency, and the gallbladder's concentrating ability. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14582?source=see_link\">",
"     \"Patient selection for the nonsurgical treatment of gallstone disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An orally administered contrast agent (eg, iopanoic acid, sodium tyropanoate, or calcium ipodate) is given and is absorbed through the intestine, taken up by the liver, and secreted into bile. Gallstones appear as filling defects within the contrast on plain x-rays (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79353 \" href=\"mobipreview.htm?2/14/2287\">",
"     image 3",
"    </a>",
"    ). Non-opacification of the gallbladder can occur due to poor absorption from the intestine, impaired liver function, or extrahepatic biliary obstruction. With the currently available oral contrast agents, it is unlikely that the gallbladder will be visualized if the serum bilirubin is greater than 2 to 3",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"   </p>",
"   <p>",
"    An approximation of gallbladder motor function can also be obtained using oral cholecystography. The patient is given a fatty meal and serial x-rays are obtained. If the gallbladder is functioning normally, there will be a decrease in gallbladder size over time. Evaluation of the gallbladder motor function is not recommended in patients who have known gallbladder stones since it may induce biliary colic or complications of gallstone disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58360586\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the symptoms seen with uncomplicated gallstone disease may also be seen with other disorders or in patients who have developed complications from their gallstones. Hence, it is important to consider alternative diagnoses prior to making a diagnosis of uncomplicated gallstone disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64850481\">",
"    <span class=\"h2\">",
"     Upper abdominal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallstone disease is usually considered as part of the differential diagnosis of patients presenting with upper abdominal symptoms. Other disorders in the differential diagnosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Esophageal chest pain",
"     </li>",
"     <li>",
"      Gastroesophageal reflux disease",
"     </li>",
"     <li>",
"      Peptic ulcer disease",
"     </li>",
"     <li>",
"      Nonulcer dyspepsia",
"     </li>",
"     <li>",
"      Hepatitis",
"     </li>",
"     <li>",
"      Functional gallbladder disorder",
"     </li>",
"     <li>",
"      Sphincter of Oddi dysfunction",
"     </li>",
"     <li>",
"      Chronic pancreatitis",
"     </li>",
"     <li>",
"      Irritable bowel syndrome",
"     </li>",
"     <li>",
"      Ischemic heart disease",
"     </li>",
"     <li>",
"      Pyelonephritis",
"     </li>",
"     <li>",
"      Ureteral calculi",
"     </li>",
"     <li>",
"      Complications of gallstone disease: acute cholecystitis, choledocholithiasis, acute pancreatitis, and acute cholangitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to remember that many of these diagnoses, such as irritable bowel syndrome, are common in the general population and thus may coexist with, but be unrelated to, gallstones. Because of this, an extensive search for gallstones in patients with nonspecific or atypical symptoms is discouraged. A general approach to the evaluation of patients with abdominal pain is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=see_link\">",
"     \"Diagnostic approach to abdominal pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=see_link\">",
"     \"Differential diagnosis of abdominal pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An important feature for differentiating uncomplicated gallstone disease from non-biliary disorders is the presence of biliary colic, which has been shown to be predictive of the presence of gallstones on imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. However, biliary colic may be present in patients with other biliary disorders, such as acute cholecystitis, choledocholithiasis, sphincter of Oddi dysfunction, and functional gallbladder disorder. (See",
"    <a class=\"local\" href=\"#H64850435\">",
"     'Other disorders with biliary-type pain'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Laboratory studies can be helpful for excluding other diagnoses and detecting complications of gallstone disease. The choice and order of testing varies depending upon the clinical presentation and suspicion for a particular diagnosis. Some commonly obtained tests include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver biochemical tests (serum aminotransferases, total bilirubin, alkaline phosphatase), which may be abnormal in patients with hepatitis, biliary tract obstruction, or (less often) acute cholecystitis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=see_link\">",
"       \"Approach to the patient with abnormal liver biochemical and function tests\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Serum amylase and lipase, which are elevated in acute pancreatitis",
"     </li>",
"     <li>",
"      Complete blood count, which may show an elevated white blood cell count in patients with acute cholecystitis or acute cholangitis",
"     </li>",
"     <li>",
"      Urine analysis, which may show evidence of a urinary tract infection or ureteral calculi",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other tests that may be indicated depending upon the patient's symptoms and history include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upper endoscopy to look for peptic ulcer disease",
"     </li>",
"     <li>",
"      Endoscopic ultrasonography to look for chronic pancreatitis",
"     </li>",
"     <li>",
"      Endoscopic retrograde cholangiopancreatography (ERCP) with sphincter of Oddi manometry to look for sphincter of Oddi dysfunction",
"     </li>",
"     <li>",
"      Cholescintigraphy with or without cholecystokinin (CCK)-stimulation to look for acute cholecystitis and functional gallbladder disorder, respectively",
"     </li>",
"     <li>",
"      Testing for ischemic heart disease",
"     </li>",
"     <li>",
"      Esophageal manometry to look for esophageal sources of chest pain, such as esophageal spasm",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64850435\">",
"    <span class=\"h2\">",
"     Other disorders with biliary-type pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute cholecystitis, choledocholithiasis, sphincter of Oddi dysfunction, and functional gallbladder disorder may all present with biliary colic. Acute cholecystitis and choledocholithiasis typically present acutely and patients often seek urgent medical attention. Sphincter of Oddi dysfunction and functional gallbladder disorder, on the other hand, may occur intermittently and may not be severe enough to prompt the patient to seek urgent evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58360623\">",
"    <span class=\"h3\">",
"     Acute cholecystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cholecystitis is the most common complication of gallstone disease and needs to be differentiated from uncomplicated gallstone disease in patients presenting with biliary colic. An episode of prolonged right upper quadrant pain (greater than four to six hours), especially if associated with fever, should arouse suspicion for acute cholecystitis as opposed to an attack of simple biliary colic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical examination can help differentiate uncomplicated gallstone disease from acute cholecystitis. While biliary colic is present in both uncomplicated gallstone disease and in acute cholecystitis, the pain in uncomplicated gallstone disease is entirely visceral in origin since the gallbladder wall is not inflamed. Thus, it is less well localized and patients do not exhibit a positive Murphy's sign on physical examination. A Murphy's sign is elicited by palpating the area of the gallbladder fossa just beneath the liver edge while the patient is asked to inspire deeply, causing the gallbladder to descend toward the examining fingers. Patients with acute cholecystitis commonly experience increased discomfort and may have an associated inspiratory arrest (a positive Murphy's sign). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory tests should be normal in patients with uncomplicated gallstone disease. On the other hand, patients with acute cholecystitis may have a leukocytosis and mild elevations in serum aminotransferases, bilirubin, and amylase. Transabdominal ultrasound findings that are not seen in patients with uncomplicated gallstone disease but that may be present with acute cholecystitis include gallbladder wall thickening or edema and a \"sonographic Murphy's sign\" in which pain is reproduced when the gallbladder is compressed by the ultrasound probe under direct ultrasonic visualization. Cholescintigraphy (99mTc-heapto-iminodiacetic acid [HIDA] scanning) is not used in the diagnosis of gallstones, but is useful in excluding acute cholecystitis in patients who present with acute biliary colic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A detailed discussion of the approach to patients with suspected acute cholecystitis is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15511?source=see_link\">",
"     \"Treatment of acute cholecystitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58365883\">",
"    <span class=\"h3\">",
"     Choledocholithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a stone in the common bile duct (choledocholithiasis) may have typical biliary colic. However, the pain is usually more prolonged than is seen with uncomplicated gallstone disease. Serum aminotransferases are normal with uncomplicated gallstone disease but are typically elevated early in the course of biliary obstruction. If the stone is not passed, a cholestatic pattern develops (increased bilirubin, alkaline phosphatase, and gamma-glutamyl transpeptidase out of proportion to the elevation in the aminotransferases). Patients who have developed acute cholangitis may also present with fever, leukocytosis, hypotension, or mental status changes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40936?source=see_link&amp;anchor=H972627928#H972627928\">",
"     \"Approach to the patient with suspected choledocholithiasis\", section on 'Laboratory evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24790?source=see_link&amp;anchor=H5#H5\">",
"     \"Acute cholangitis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transabdominal ultrasound may reveal a stone in the common bile duct, but the sensitivity is poor for stones in the distal common bile duct. A dilated common bile duct supports a diagnosis of choledocholithiasis, but is not specific. Magnetic resonance cholangiopancreatography, endoscopic ultrasound, or ERCP may be required to confirm the diagnosis, and in the case of ERCP, provide therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40936?source=see_link&amp;anchor=H972627978#H972627978\">",
"     \"Approach to the patient with suspected choledocholithiasis\", section on 'Imaging tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to the diagnosis and management of patients with choledocholithiasis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40936?source=see_link\">",
"     \"Approach to the patient with suspected choledocholithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58365923\">",
"    <span class=\"h3\">",
"     Sphincter of Oddi dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term sphincter of Oddi dysfunction (SOD) has been used to describe a clinical syndrome of biliary or pancreatic obstruction related to mechanical or functional abnormalities of the sphincter of Oddi. Patients with SOD may have biliary colic that lasts from about 30 minutes to several hours. Unlike patients with uncomplicated gallstone disease, patients with SOD may have elevations in their aminotransferases, alkaline phosphatase, amylase, or lipase. In addition, the common bile duct may appear dilated on transabdominal ultrasound. In some cases, sphincter of Oddi manometry may be required to confirm the diagnosis of SOD.",
"   </p>",
"   <p>",
"    The approach to patients with suspected Sphincter of Oddi is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12874?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sphincter of Oddi dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29126?source=see_link\">",
"     \"Treatment of sphincter of Oddi dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58365735\">",
"    <span class=\"h3\">",
"     Functional gallbladder disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional gallbladder disorder is a diagnosis of exclusion. Patients with functional gallbladder disorder have biliary colic, but do not have gallstones, sludge, or microlithiasis. To differentiate functional gallbladder disorder from uncomplicated gallstone disease, patients must have a thorough evaluation for gallstones and other disorders that may cause upper abdominal symptoms. If this testing is negative, patients then undergo CCK-stimulated cholescintigraphy to determine the gallbladder ejection fraction, which is low in patients with functional gallbladder disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8200?source=see_link&amp;anchor=H366143604#H366143604\">",
"     \"Functional gallbladder disorder in adults\", section on 'CCK-stimulated cholescintigraphy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Functional gallbladder disorder is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8200?source=see_link\">",
"     \"Functional gallbladder disorder in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the management of patients with gallstones depends upon the patient's symptoms, imaging test findings, and whether complications are present. In general, patients with sludge or microlithiasis are managed the same as patients with gallstones. Most asymptomatic patients are followed expectantly, whereas patients with recurrent severe symptoms are treated with pain control and cholecystectomy. The management of patients with atypical or mild symptoms and gallstones or with typical biliary colic but no gallstones is more complicated and may include empiric treatments for other disorders or, in appropriately selected patients, cholecystectomy.",
"   </p>",
"   <p>",
"    We have found it useful to divide patients into four categories to help guide management:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Category 1: Patients with gallstones but no symptoms",
"     </li>",
"     <li>",
"      Category 2: Patients with typical biliary symptoms and gallstones",
"     </li>",
"     <li>",
"      Category 3: Patients with gallstones but atypical symptoms",
"     </li>",
"     <li>",
"      Category 4: Patients with typical biliary symptoms but without gallstones on ultrasound",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The management of patients with complications due to gallstones is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15511?source=see_link\">",
"     \"Treatment of acute cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40936?source=see_link&amp;anchor=H972628735#H972628735\">",
"     \"Approach to the patient with suspected choledocholithiasis\", section on 'Approach to diagnosis and management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/35/7738?source=see_link\">",
"     \"Treatment of acute pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24790?source=see_link\">",
"     \"Acute cholangitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/62/26598?source=see_link&amp;anchor=H7#H7\">",
"     \"Gallstone ileus\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44565?source=see_link&amp;anchor=H7#H7\">",
"     \"Mirizzi syndrome\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/12/22730?source=see_link\">",
"     \"Surgical management of gallbladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/24/43399?source=see_link\">",
"     \"Adjuvant treatment for localized, potentially resectable gallbladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33977?source=see_link\">",
"     \"Treatment of advanced, unresectable gallbladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22973321\">",
"    <span class=\"h2\">",
"     Category 1 patients (gallstones but no symptoms)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who are asymptomatic but found to have incidental gallstones on an imaging test do not require treatment since the risk of developing life-threatening, severe complications is low. This recommendation is based upon studies showing that the rate of progression from asymptomatic to symptomatic gallstones is very low (about 1 percent per year). In addition, when patients do become symptomatic, the initial presenting symptoms are usually not severe, allowing for cholecystectomy at that time. As a result, most patients with incidental gallstones can be educated about potentially concerning symptoms, so they may seek medical attention before severe complications arise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10374?source=see_link\">",
"     \"Approach to the patient with incidental gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some patients may be at increased risk for complications or cancer, and in such patients prophylactic cholecystectomy may be warranted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10374?source=see_link&amp;anchor=H5#H5\">",
"     \"Approach to the patient with incidental gallstones\", section on 'Patients at increased risk of complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some data suggest that physical activity may reduce the risk of developing symptomatic gallstone disease. In a study of more than 60,000 women, women who were seated for less than six hours per week were less likely to undergo cholecystectomy compared with those who sat for 41 to 60 hours or more than 60 hours (relative risks 1.4 and 2.3, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/53\">",
"     53",
"    </a>",
"    ]. In a second study, there was a three-fold increase in gallstone disease among men who watched television for more than 40 hours per week compared with those who watched for less than six hours per week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1067517491\">",
"    <span class=\"h2\">",
"     Category 2 patients (typical biliary symptoms and gallstones)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a classic presentation of uncomplicated gallstone disease there are two general considerations when it comes to management:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute management of biliary colic.",
"     </li>",
"     <li>",
"      Prophylactic treatment: In contrast to patients with incidental gallstones, prophylactic treatment to remove the offending stones (typically by cholecystectomy) is recommended for patients with gallstone disease, both to prevent future attacks of biliary colic and to prevent the complications of gallstone disease. Whether to perform prophylactic cholecystectomy in patients with mild symptoms depends upon factors such as the patient's age, comorbid illnesses, and the frequency of attacks. (See",
"      <a class=\"local\" href=\"#H243183886\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8997696\">",
"    <span class=\"h3\">",
"     Pain management",
"    </span>",
"    &nbsp;&mdash;&nbsp;During an acute attack of biliary colic, management is focused on pain control. Pain control can usually be achieved with nonsteroidal antiinflammatory drugs (NSAIDs) or opioids. Those with prolonged attacks (especially if accompanied by vomiting) should also receive intravenous hydration.",
"   </p>",
"   <p>",
"    We prefer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    (30 to 60 mg adjusted for age and renal function given in a single intravenous or intramuscular dose) for patients who present to the emergency department with biliary colic. Treatment usually relieves symptoms within 10 to 30 minutes. Patients are then prescribed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    400 mg orally for subsequent attacks that may occur while the patient is awaiting cholecystectomy. We reserve opioids for patients who have contraindications to NSAIDs or who do not achieve adequate pain relief with an NSAID.",
"   </p>",
"   <p>",
"    The role for NSAIDs in the treatment of biliary colic was demonstrated in a meta-analysis of 11 randomized trials with 1076 patients that compared NSAIDs with no treatment, placebo, or other treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/55\">",
"     55",
"    </a>",
"    ]. NSAIDs were more likely to control pain than placebo (relative risk [RR] 3.8; 95% confidence interval [CI] 1.7-8.6) or antispasmodics (RR 1.5; 95% CI 1.0-2.1). In addition, there was no difference in pain control between NSAIDs and opioids (RR 1.1; 95% CI 0.8-1.3). NSAIDs may also favorably alter the natural history of biliary colic, possibly due to the role of prostaglandins in the development of acute cholecystitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Opioids, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    , are an alternative for patients who cannot take NSAIDs or who fail to respond to an NSAID. It has traditionally been taught that meperidine is the narcotic of choice in patients with biliary colic or gallstone pancreatitis because it has less of an effect on sphincter of Oddi motility than morphine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. However, a systematic review found that all opioids result in increased sphincter of Oddi pressure when measured using sphincter of Oddi manometry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/59\">",
"     59",
"    </a>",
"    ]. In addition, there are no clinical studies comparing meperidine and morphine, nor are there clinical studies to suggest that morphine causes pancreatitis or cholecystitis. Thus, there are insufficient data to suggest that morphine should be avoided in patients with biliary colic. In addition, morphine has the benefit of having a longer half-life than meperidine. Meperidine's short half-life may lead to the need for frequent dosing, resulting in the accumulation of the metabolite normeperidine, which causes neuromuscular irritation and, rarely, seizures.",
"   </p>",
"   <p>",
"    While anticholinergic agents are useful in the management of renal colic due to their smooth muscle relaxation effects, they do not appear to help biliary colic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Cholecystectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive prophylactic therapy to prevent future attacks of biliary colic and to prevent the complications of gallstone disease is appropriate for patients with recurrent attacks of moderate or severe biliary colic, or with an isolated severe attack. Several modalities are available ranging from cholecystectomy to medical dissolution of the stones. Cholecystectomy is recommended for the majority of patients, but medical dissolution or extracorporeal shock-wave lithotripsy therapy may be appropriate for patients who are poor surgical candidates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6408?source=see_link&amp;anchor=H3#H3\">",
"     \"Dissolution therapy for the treatment of gallstones\", section on 'Medical gallstone dissolution'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36489?source=see_link\">",
"     \"Open cholecystectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11338?source=see_link\">",
"     \"Laparoscopic cholecystectomy: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to treatment is not as clear for patients with isolated or recurrent attacks of mild biliary colic. Such patients are at low risk for developing complications (one to two percent per year). The decision to proceed with prophylactic cholecystectomy in such patients should take into account factors such as the patient's age (younger patients are more likely to develop complications due to their longer life-expectancy), the frequency of the attacks (with more frequent attacks favoring prophylactic therapy), the patient's surgical risk, and the patient's attitudes toward surgery and expectant management (eg, some patients may be more concerned about a severe complication than undergoing a surgical procedure, whereas others may prefer to avoid surgery and are willing to accept the risk of developing a gallstone-related complication). Another option for patients in this group that we frequently offer is oral dissolution therapy with bile acids. Studies suggest that long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    therapy of 600 mg per day reduces the risk of biliary complications and the need for a cholecystectomy by 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6408?source=see_link&amp;anchor=H4#H4\">",
"     \"Dissolution therapy for the treatment of gallstones\", section on 'Bile acid therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64850949\">",
"    <span class=\"h4\">",
"     Surgical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholecystectomy is typically preformed laparoscopically, though it may also be performed through an open right upper quadrant incision. A laparoscopic approach eliminates the need to cut the rectus abdominis muscle and is associated with less postoperative pain, better cosmesis, shorter hospital stays, and less time off from work than open cholecystectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/63-67\">",
"     63-67",
"    </a>",
"    ]. However, the laparoscopic procedure has been associated with an increased risk of common bile duct injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. In addition, the laparoscopic procedure may require conversion to an open procedure due to a variety of technical or patient issues. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64850928\">",
"    <span class=\"h4\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While patients with biliary colic and gallstones on imaging usually respond well to cholecystectomy, it is not always curative. In a systematic review of 23 studies looking at the effect of cholecystectomy for patients with gallstones, 92 percent of patients with biliary colic had symptom relief following cholecystectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that predict a response to cholecystectomy were evaluated in a study of 1008 patients with upper abdominal pain and gallstones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/70\">",
"     70",
"    </a>",
"    ]. Upper abdominal pain relief was reported by 594 patients (59 percent) following cholecystectomy. On multivariable analysis, factors associated with pain relief following cholecystectomy included pain that occurred once a month or less (odds ratio [OR] 1.6), pain that began one year or less prior to surgery (OR 1.3), and pain that awakened the patient at night (OR 1.5). Factors associated with a lower likelihood of achieving pain relief were the presence of lower abdominal pain (OR 0.7), usually having an abnormal bowel pattern (OR 0.6), and often feeling bloated or \"burpy\" (OR 0.6).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64850996\">",
"    <span class=\"h4\">",
"     Complications and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major complications have been reported to occur in 2.6 percent of laparoscopic cholecystectomies and include bleeding, abscess formation, bile leak, biliary injury, and bowel injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While removal of the gallbladder is commonly considered to have no lasting physiologic consequences, 5 to 12 percent of patients develop diarrhea, though in many cases the diarrhea will improve or resolve over weeks to months. Increased risks of right sided colon cancer, esophageal cancer, and small intestinal cancer in patients who have undergone cholecystectomy have also been suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. This may be related to the effects of increased concentrations of the bile acid deoxycholic acid in the gut lumen as a result of loss of the gallbladder, which normally acts as a reservoir for concentrated bile acids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/55/43897?source=see_link&amp;anchor=H16433027#H16433027\">",
"     \"Approach to the adult with chronic diarrhea in developed countries\", section on 'Cholecystectomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=see_link&amp;anchor=H11#H11\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\", section on 'Cholecystectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64850956\">",
"    <span class=\"h4\">",
"     Alternatives to cholecystectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, surgical removal of the gallbladder may not be feasible, usually because of patient comorbidities. Several nonsurgical techniques for treatment of gallstones have been developed. These include medical dissolution therapy with oral bile acids and extracorporeal shock-wave lithotripsy. While the development of laparoscopic cholecystectomy has generally reduced enthusiasm for these approaches, they remain reasonable options in selected patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14582?source=see_link\">",
"     \"Patient selection for the nonsurgical treatment of gallstone disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6408?source=see_link\">",
"     \"Dissolution therapy for the treatment of gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22973264\">",
"    <span class=\"h2\">",
"     Category 3 patients (gallstones but atypical symptoms)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with atypical symptoms and gallstones respond to cholecystectomy, but the response rates are lower than those seen for patients with typical biliary colic. This suggests that in some patients, the atypical symptoms are related to the gallstones, but that in others they are due to another cause and the gallstones are an incidental finding. Thus, a careful search for other causes of a patient's atypical symptoms is indicated. However, symptoms as described by patients are highly subjective and often change. As a result, it is useful to review the symptoms on more than one occasion to see if a patient has developed biliary colic. (See",
"    <a class=\"local\" href=\"#H58360586\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The probability of patients with atypical symptoms and gallstones responding to cholecystectomy was evaluated in a systematic review. Among patients with upper abdominal pain (but not necessarily biliary colic), the relief rates for elective and acute cholecystectomy were 72 and 86 percent, respectively. In patients with dyspeptic symptoms, the relief rates were 56 and 82 percent, respectively. In addition, 65 percent of patients with food intolerance reported relief after 12 months.",
"   </p>",
"   <p>",
"    An empiric trial of oral dissolution therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (UDCA) may help identify patients who will benefit from cholecystectomy, provided there has been a thorough evaluation for other causes of the symptoms. UDCA therapy relieves the symptoms in many patients within three months if the symptoms are due to gallstones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/74\">",
"     74",
"    </a>",
"    ]. While UDCA therapy may provide symptomatic relief, the rates of complete stone dissolution are poor (37 percent in a meta-analysis), leaving patients at risk for complications from their gallstones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/62/31722/abstract/75\">",
"     75",
"    </a>",
"    ]. As a result, we refer patients who respond to UDCA for cholecystectomy if they are surgical candidates, especially if they are not interested in staying on UDCA for two to three years to see if their stones will dissolve. We do not suggest cholecystectomy in patients who fail to respond to UDCA, and instead treat for disorders more consistent with the patient's symptoms (eg, functional dyspepsia in a patient with bloating). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6408?source=see_link\">",
"     \"Dissolution therapy for the treatment of gallstones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/28/35272?source=see_link&amp;anchor=H171654228#H171654228\">",
"     \"Functional dyspepsia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8997815\">",
"    <span class=\"h2\">",
"     Category 4 patients (typical biliary symptoms but without gallstones on ultrasound)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with biliary colic but no gallstones or other non-biliary causes for the pain detected after a thorough evaluation may have functional gallbladder disorder. If cholecystokinin-stimulated cholescintigraphy reveals a low gallbladder ejection fraction, a finding that is suggestive of functional gallbladder disorder, the appropriate treatment is cholecystectomy. However, if the evaluation for functional gallbladder disorder is negative, patients are generally treated for functional dyspepsia or irritable bowel syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/28/35272?source=see_link&amp;anchor=H171654228#H171654228\">",
"     \"Functional dyspepsia\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/14/40169?source=see_link\">",
"     \"Treatment of irritable bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2890985\">",
"    <span class=\"h2\">",
"     Patients with gallstone-related complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications of cholelithiasis include acute cholecystitis, choledocholithiasis, gallstone pancreatitis, acute cholangitis, gallstone ileus, Mirizzi syndrome, and gallbladder cancer. The management of these complications is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15511?source=see_link\">",
"     \"Treatment of acute cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40936?source=see_link&amp;anchor=H972628735#H972628735\">",
"     \"Approach to the patient with suspected choledocholithiasis\", section on 'Approach to diagnosis and management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/35/7738?source=see_link\">",
"     \"Treatment of acute pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24790?source=see_link\">",
"     \"Acute cholangitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/62/26598?source=see_link&amp;anchor=H7#H7\">",
"     \"Gallstone ileus\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44565?source=see_link&amp;anchor=H7#H7\">",
"     \"Mirizzi syndrome\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/12/22730?source=see_link\">",
"     \"Surgical management of gallbladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/24/43399?source=see_link\">",
"     \"Adjuvant treatment for localized, potentially resectable gallbladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33977?source=see_link\">",
"     \"Treatment of advanced, unresectable gallbladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2891157\">",
"    <span class=\"h2\">",
"     Women with gallstones who are pregnant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to women with gallstones who are pregnant is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28201?source=see_link\">",
"     \"Gallstone disease in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/29/8658?source=see_link\">",
"       \"Patient information: Gallstones (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/56/1923?source=see_link\">",
"       \"Patient information: Gallbladder removal (cholecystectomy) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/21/7507?source=see_link\">",
"       \"Patient information: Gallstones (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with uncomplicated gallstone disease typically present with biliary colic, normal physical examination findings, and normal laboratory test results. Biliary colic is often associated with diaphoresis, nausea, and vomiting. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications from asymptomatic gallstones occur at a rate of approximately one to two percent per year but are more common in patients with symptomatic gallstones. Complications include acute cholecystitis, choledocholithiasis with or without acute cholangitis, and gallstone pancreatitis. Rare complications include gallbladder cancer, gallstone ileus, and Mirizzi syndrome. (See",
"      <a class=\"local\" href=\"#H243183886\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typically, the evaluation of a patient with biliary colic begins with a transabdominal ultrasound. If the ultrasound is negative, additional studies that may help with the diagnosis include repeating the transabdominal ultrasound, endoscopic ultrasound, and bile microscopy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with uncomplicated gallstone disease may have ultrasound findings of gallstones, gravel, or sludge. Distinguishing among these three entities is generally not clinically important because they are managed identically. On ultrasound, gallstones appear as echogenic foci that cast an acoustic shadow (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70175 \" href=\"mobipreview.htm?41/14/42211\">",
"       image 2",
"      </a>",
"      ) and seek gravitational dependency. Gravel is the appearance of multiple small stones that are echogenic and cast shadows. Sludge, which represents cholesterol crystals and bilirubinate particles in a mucus glycoprotein gel, is echogenic in appearance but does not cast an acoustic shadow. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Transabdominal ultrasound'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gallstone disease is usually considered as part of the differential diagnosis of patients presenting with upper abdominal symptoms. Thus, the decision to implicate the gallbladder has to be made based upon clinical suspicion for a varied group of disorders that include peptic ulcer disease, nonulcer dyspepsia, functional gallbladder disorder, sphincter of Oddi dysfunction, and ischemic heart disease. In addition, complications related to gallstones, such as acute cholecystitis, choledocholithiasis, pancreatitis, and acute cholangitis also need to be considered. (See",
"      <a class=\"local\" href=\"#H58360586\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The approach to management of patients with uncomplicated gallstones or simple biliary colic depends upon the patient's symptoms and imaging test findings. We have found it useful to divide patients into four categories to help guide management:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Category 1: Patients with gallstones but no symptoms",
"     </li>",
"     <li>",
"      Category 2: Patients with typical biliary symptoms and gallstones",
"     </li>",
"     <li>",
"      Category 3: Patients with gallstones but atypical symptoms",
"     </li>",
"     <li>",
"      Category 4: Patients with typical biliary symptoms but without gallstones on ultrasound",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Category 1",
"      </strong>",
"      : The majority of patients with asymptomatic (incidental) gallstones do not require treatment because they are unlikely to develop symptoms and, if symptoms do occur, they are generally mild initially. However, patients must be educated about the symptoms of gallstone disease so they can seek treatment before more severe symptoms or complications develop. On the other hand, cholecystectomy may be a reasonable alternative in patients at increased risk for complications or gallbladder cancer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10374?source=see_link\">",
"       \"Approach to the patient with incidental gallstones\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Category 2",
"      </strong>",
"      : For patients with recurrent attacks of moderate or severe biliary colic, or with an isolated severe attack, and gallstones on imaging, we recommend cholecystectomy rather than expectant management (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Such patients are likely to have recurrent attacks and are at risk for complications. Dissolution therapy or extracorporeal shock-wave lithotripsy is a reasonable alternative in patients who are not surgical candidates. (See",
"      <a class=\"local\" href=\"#H1067517491\">",
"       'Category 2 patients (typical biliary symptoms and gallstones)'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Options for treating patients with mild symptoms include expectant management, prophylactic cholecystectomy, and oral dissolution therapy with bile acids. The choice of therapy will depend on factors such as the patient's age (younger patients are more likely to develop complications due to their longer life-expectancy), the frequency of the attacks (with more frequent attacks favoring prophylactic therapy), the patient's surgical risk, and the patient's attitudes toward surgery and expectant management.",
"     </li>",
"     <li>",
"      <strong>",
"       Category 3",
"      </strong>",
"      : For patients with atypical symptoms and gallstones, we suggest additional evaluation rather than cholecystectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Such patients should be thoroughly evaluated for non-gallstone-related causes of their symptoms. Cholecystectomy is a reasonable alternative if a thorough evaluation for other causes of the patient's symptoms is negative and if the patient has a symptomatic response to dissolution therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"       ursodeoxycholic acid",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H22973264\">",
"       'Category 3 patients (gallstones but atypical symptoms)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H58360586\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Category 4",
"      </strong>",
"      : Patients with biliary colic but no gallstones detected after a thorough evaluation for both biliary and non-biliary causes of their pain should be evaluated for functional gallbladder disorder, as patients with functional gallbladder disorder often respond to cholecystectomy. If the evaluation for functional gallbladder disorder is negative, patients are generally treated for functional dyspepsia or irritable bowel syndrome. (See",
"      <a class=\"local\" href=\"#H8997815\">",
"       'Category 4 patients (typical biliary symptoms but without gallstones on ultrasound)'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8200?source=see_link\">",
"       \"Functional gallbladder disorder in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/28/35272?source=see_link&amp;anchor=H171654228#H171654228\">",
"       \"Functional dyspepsia\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/14/40169?source=see_link\">",
"       \"Treatment of irritable bowel syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The management of patients with gallstone-related complications (eg, acute cholecystitis, gallstone pancreatitis, or acute cholangitis) is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15511?source=see_link\">",
"       \"Treatment of acute cholecystitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40936?source=see_link&amp;anchor=H972628735#H972628735\">",
"       \"Approach to the patient with suspected choledocholithiasis\", section on 'Approach to diagnosis and management'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/35/7738?source=see_link\">",
"       \"Treatment of acute pancreatitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24790?source=see_link\">",
"       \"Acute cholangitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/62/26598?source=see_link&amp;anchor=H7#H7\">",
"       \"Gallstone ileus\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44565?source=see_link&amp;anchor=H7#H7\">",
"       \"Mirizzi syndrome\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/12/22730?source=see_link\">",
"       \"Surgical management of gallbladder cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/24/43399?source=see_link\">",
"       \"Adjuvant treatment for localized, potentially resectable gallbladder cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33977?source=see_link\">",
"       \"Treatment of advanced, unresectable gallbladder cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/1\">",
"      Gracie WA, Ransohoff DF. The natural history of silent gallstones: the innocent gallstone is not a myth. N Engl J Med 1982; 307:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/2\">",
"      Festi D, Reggiani ML, Attili AF, et al. Natural history of gallstone disease: Expectant management or active treatment? Results from a population-based cohort study. J Gastroenterol Hepatol 2010; 25:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/3\">",
"      Friedman GD. Natural history of asymptomatic and symptomatic gallstones. Am J Surg 1993; 165:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/4\">",
"      Friedman GD, Raviola CA, Fireman B. Prognosis of gallstones with mild or no symptoms: 25 years of follow-up in a health maintenance organization. J Clin Epidemiol 1989; 42:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/5\">",
"      Diehl AK, Sugarek NJ, Todd KH. Clinical evaluation for gallstone disease: usefulness of symptoms and signs in diagnosis. Am J Med 1990; 89:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/6\">",
"      LUND J. Surgical indications in cholelithiasis: prophylactic choleithiasis: prophylactic cholecystectomy elucidated on the basis of long-term follow up on 526 nonoperated cases. Ann Surg 1960; 151:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/7\">",
"      Festi D, Sottili S, Colecchia A, et al. Clinical manifestations of gallstone disease: evidence from the multicenter Italian study on cholelithiasis (MICOL). Hepatology 1999; 30:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/8\">",
"      Rigas B, Torosis J, McDougall CJ, et al. The circadian rhythm of biliary colic. J Clin Gastroenterol 1990; 12:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/9\">",
"      Minoli G, Imperiale G, Spinzi GC, et al. Circadian periodicity and other clinical features of biliary pain. J Clin Gastroenterol 1991; 13:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/10\">",
"      Zakko SF, Guttermuth MC, Jamali SH, et al. A population study of gallstone composition, symptoms, and outcomes after cholecystectomy (abstract). Gastroenterology 1999; 116:A43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/11\">",
"      Berger MY, Olde Hartman TC, Bohnen AM. Abdominal symptoms: do they disappear after cholecystectomy? Surg Endosc 2003; 17:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/12\">",
"      Johnson CD. ABC of the upper gastrointestinal tract. Upper abdominal pain: Gall bladder. BMJ 2001; 323:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/13\">",
"      Barakos JA, Ralls PW, Lapin SA, et al. Cholelithiasis: evaluation with CT. Radiology 1987; 162:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/14\">",
"      Benarroch-Gampel J, Boyd CA, Sheffield KM, et al. Overuse of CT in patients with complicated gallstone disease. J Am Coll Surg 2011; 213:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/15\">",
"      Leopold GR, Amberg J, Gosink BB, Mittelstaedt C. Gray scale ultrasonic cholecystography: a comparison with conventional radiographic techniques. Radiology 1976; 121:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/16\">",
"      Conrad MR, Janes JO, Dietchy J. Significance of low level echoes within the gallbladder. AJR Am J Roentgenol 1979; 132:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/17\">",
"      Brink JA, Simeone JF, Mueller PR, et al. Physical characteristics of gallstones removed at cholecystectomy: implications for extracorporeal shock-wave lithotripsy. AJR Am J Roentgenol 1988; 151:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/18\">",
"      Filly RA, Allen B, Minton MJ, et al. In vitro investigation of the origin of echoes with biliary sludge. J Clin Ultrasound 1980; 8:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/19\">",
"      Ko CW, Sekijima JH, Lee SP. Biliary sludge. Ann Intern Med 1999; 130:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/20\">",
"      Lee SP, Nicholls JF. Nature and composition of biliary sludge. Gastroenterology 1986; 90:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/21\">",
"      Venu RP, Geenen JE, Hogan W, et al. Idiopathic recurrent pancreatitis. An approach to diagnosis and treatment. Dig Dis Sci 1989; 34:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/22\">",
"      Lee SP, Maher K, Nicholls JF. Origin and fate of biliary sludge. Gastroenterology 1988; 94:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/23\">",
"      Lee SP, Nicholls JF, Park HZ. Biliary sludge as a cause of acute pancreatitis. N Engl J Med 1992; 326:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/24\">",
"      Neoptolemos JP, Davidson BR, Winder AF, Vallance D. Role of duodenal bile crystal analysis in the investigation of 'idiopathic' pancreatitis. Br J Surg 1988; 75:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/25\">",
"      Geenen JE, Nash JA. The role of sphincter of Oddi manometry and biliary microscopy in evaluating idiopathic recurrent pancreatitis. Endoscopy 1998; 30:A237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/26\">",
"      Britten JS, Golding RH, Cooperberg PL. Sludge balls to gallstones. J Ultrasound Med 1984; 3:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/27\">",
"      Feuerstein IM, Shawker TH, Savarese DM. CT demonstration of calcifying sludge balls. J Comput Assist Tomogr 1990; 14:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/28\">",
"      Shea JA, Berlin JA, Escarce JJ, et al. Revised estimates of diagnostic test sensitivity and specificity in suspected biliary tract disease. Arch Intern Med 1994; 154:2573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/29\">",
"      Garra BS, Davros WJ, Lack EE, et al. Visibility of gallstone fragments at US and fluoroscopy: implications for monitoring gallstone lithotripsy. Radiology 1990; 174:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/30\">",
"      Wermke W. [Ultrasonic diagnosis of gallstone diseases]. Z Gesamte Inn Med 1989; 44:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/31\">",
"      Kurol M, Forsberg L. Ultrasonography in the diagnosis of acute cholecystitis. Acta Radiol Diagn (Stockh) 1984; 25:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/32\">",
"      Venu RP, Geenen JE, Toouli J, et al. Endoscopic retrograde cholangiopancreatography. Diagnosis of cholelithiasis in patients with normal gallbladder x-ray and ultrasound studies. JAMA 1983; 249:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/33\">",
"      Zakko SF, Srb S, Ramsby GR. Sensitivity of percutaneous endoscopy compared with ultrasonography in the detection of residue or mucosal lesions after topical gallbladder stone dissolution. Gastrointest Endosc 1995; 42:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/34\">",
"      Neoptolemos JP, Hall AW, Finlay DF, et al. The urgent diagnosis of gallstones in acute pancreatitis: a prospective study of three methods. Br J Surg 1984; 71:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/35\">",
"      Dahan P, Andant C, L&eacute;vy P, et al. Prospective evaluation of endoscopic ultrasonography and microscopic examination of duodenal bile in the diagnosis of cholecystolithiasis in 45 patients with normal conventional ultrasonography. Gut 1996; 38:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/36\">",
"      Liu CL, Lo CM, Chan JK, et al. EUS for detection of occult cholelithiasis in patients with idiopathic pancreatitis. Gastrointest Endosc 2000; 51:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/37\">",
"      Dill JE, Hill S, Callis J, et al. Combined endoscopic ultrasound and stimulated biliary drainage in cholecystitis and microlithiasis--diagnoses and outcomes. Endoscopy 1995; 27:424.",
"     </a>",
"    </li>",
"    <li>",
"     Norton SA, Alderson D. The value of endoscopic ultrasonography (EUS) in the assessment of idiopathic pancreatitis. In: Program and Abstracts, 11th International Symposium on Endoscopic Ultrasonography, Kyoto, Japan 1998. p.39.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/39\">",
"      Delchier JC, Benfredj P, Preaux AM, et al. The usefulness of microscopic bile examination in patients with suspected microlithiasis: a prospective evaluation. Hepatology 1986; 6:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/40\">",
"      Moskovitz M, Min TC, Gavaler JS. The microscopic examination of bile in patients with biliary pain and negative imaging tests. Am J Gastroenterol 1986; 81:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/41\">",
"      Burnstein MJ, Vassal KP, Strasberg SM. Results of combined biliary drainage and cholecystokinin cholecystography in 81 patients with normal oral cholecystograms. Ann Surg 1982; 196:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/42\">",
"      Ramond MJ, Dumont M, Belghiti J, Erlinger S. Sensitivity and specificity of microscopic examination of gallbladder bile for gallstone recognition and identification. Gastroenterology 1988; 95:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/43\">",
"      Sedaghat A, Grundy SM. Cholesterol crystals and the formation of cholesterol gallstones. N Engl J Med 1980; 302:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/44\">",
"      Gollish SH, Burnstein MJ, Ilson RG, et al. Nucleation of cholesterol monohydrate crystals from hepatic and gall-bladder bile of patients with cholesterol gall stones. Gut 1983; 24:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/45\">",
"      Abeysuriya V, Deen KI, Navarathne NM. Biliary microlithiasis, sludge, crystals, microcrystallization, and usefulness of assessment of nucleation time. Hepatobiliary Pancreat Dis Int 2010; 9:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/46\">",
"      Rashdan A, Fogel E, McHenry L Jr, et al. Frequency of biliary crystals in patients with suspected sphincter of Oddi dysfunction. Gastrointest Endosc 2003; 58:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/47\">",
"      Corazziari E, Shaffer EA, Hogan WJ, et al. Functional disorders of the biliary tract and Pancreas. Gut 1999; 45 Suppl 2:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/48\">",
"      Ziessman HA, Fahey FH, Hixson DJ. Calculation of a gallbladder ejection fraction: advantage of continuous sincalide infusion over the three-minute infusion method. J Nucl Med 1992; 33:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/49\">",
"      Marks JW, Bonorris G. Intermittency of cholesterol crystals in duodenal bile from gallstone patients. Gastroenterology 1984; 87:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/50\">",
"      Graham EA, Cole WH, Copher GH. Visualization of the gallbladder by the sodium salt of tetrabromophthalein. JAMA 1924; 82:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/51\">",
"      Kraag N, Thijs C, Knipschild P. Dyspepsia--how noisy are gallstones? A meta-analysis of epidemiologic studies of biliary pain, dyspeptic symptoms, and food intolerance. Scand J Gastroenterol 1995; 30:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/52\">",
"      Berger MY, van der Velden JJ, Lijmer JG, et al. Abdominal symptoms: do they predict gallstones? A systematic review. Scand J Gastroenterol 2000; 35:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/53\">",
"      Leitzmann MF, Rimm EB, Willett WC, et al. Recreational physical activity and the risk of cholecystectomy in women. N Engl J Med 1999; 341:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/54\">",
"      Leitzmann MF, Giovannucci EL, Rimm EB, et al. The relation of physical activity to risk for symptomatic gallstone disease in men. Ann Intern Med 1998; 128:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/55\">",
"      Colli A, Conte D, Valle SD, et al. Meta-analysis: nonsteroidal anti-inflammatory drugs in biliary colic. Aliment Pharmacol Ther 2012; 35:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/56\">",
"      Henderson SO, Swadron S, Newton E. Comparison of intravenous ketorolac and meperidine in the treatment of biliary colic. J Emerg Med 2002; 23:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/57\">",
"      Akriviadis EA, Hatzigavriel M, Kapnias D, et al. Treatment of biliary colic with diclofenac: a randomized, double-blind, placebo-controlled study. Gastroenterology 1997; 113:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/58\">",
"      Elta GH, Barnett JL. Meperidine need not be proscribed during sphincter of Oddi manometry. Gastrointest Endosc 1994; 40:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/59\">",
"      Thompson DR. Narcotic analgesic effects on the sphincter of Oddi: a review of the data and therapeutic implications in treating pancreatitis. Am J Gastroenterol 2001; 96:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/60\">",
"      Thune A, Baker RA, Saccone GT, et al. Differing effects of pethidine and morphine on human sphincter of Oddi motility. Br J Surg 1990; 77:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/61\">",
"      Tytgat GN. Hyoscine butylbromide - a review on its parenteral use in acute abdominal spasm and as an aid in abdominal diagnostic and therapeutic procedures. Curr Med Res Opin 2008; 24:3159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/62\">",
"      Tomida S, Abei M, Yamaguchi T, et al. Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: a cohort analysis. Hepatology 1999; 30:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/63\">",
"      Soper NJ, Stockmann PT, Dunnegan DL, Ashley SW. Laparoscopic cholecystectomy. The new 'gold standard'? Arch Surg 1992; 127:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/64\">",
"      Schirmer BD, Edge SB, Dix J, et al. Laparoscopic cholecystectomy. Treatment of choice for symptomatic cholelithiasis. Ann Surg 1991; 213:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/65\">",
"      Wiesen SM, Unger SW, Barkin JS, et al. Laparoscopic cholecystectomy: the procedure of choice for acute cholecystitis. Am J Gastroenterol 1993; 88:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/66\">",
"      Wilson RG, Macintyre IM, Nixon SJ, et al. Laparoscopic cholecystectomy as a safe and effective treatment for severe acute cholecystitis. BMJ 1992; 305:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/67\">",
"      Yamashita Y, Takada T, Kawarada Y, et al. Surgical treatment of patients with acute cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg 2007; 14:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/68\">",
"      Bernard HR, Hartman TW. Complications after laparoscopic cholecystectomy. Am J Surg 1993; 165:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/69\">",
"      National Institutes of Health Consensus Development Conference Statement on Gallstones and Laparoscopic Cholecystectomy. Am J Surg 1993; 165:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/70\">",
"      Thistle JL, Longstreth GF, Romero Y, et al. Factors that predict relief from upper abdominal pain after cholecystectomy. Clin Gastroenterol Hepatol 2011; 9:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/71\">",
"      Giovannucci E, Colditz GA, Stampfer MJ. A meta-analysis of cholecystectomy and risk of colorectal cancer. Gastroenterology 1993; 105:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/72\">",
"      Shao T, Yang YX. Cholecystectomy and the risk of colorectal cancer. Am J Gastroenterol 2005; 100:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/73\">",
"      Lagergren J, Ye W, Ekbom A. Intestinal cancer after cholecystectomy: is bile involved in carcinogenesis? Gastroenterology 2001; 121:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/74\">",
"      Tint GS, Salen G, Colalillo A, et al. Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones. Ann Intern Med 1982; 97:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/62/31722/abstract/75\">",
"      Rubin RA, Kowalski TE, Khandelwal M, Malet PF. Ursodiol for hepatobiliary disorders. Ann Intern Med 1994; 121:207.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 654 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-3A9BE56C6A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_62_31722=[""].join("\n");
var outline_f30_62_31722=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H73972061\">",
"      CATEGORIZATION OF PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H243183886\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8995491\">",
"      Biliary colic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22973364\">",
"      Atypical symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8995514\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8995574\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58365548\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Transabdominal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58361345\">",
"      - Characteristics of stones on ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58360944\">",
"      - Test characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150685460\">",
"      Next steps if the ultrasound is negative",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H65536788\">",
"      - General approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H65536795\">",
"      - Repeat transabdominal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58361831\">",
"      - Endoscopic ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8996071\">",
"      - Bile microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H64850136\">",
"      Bile collection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8997053\">",
"      Tests that are rarely done",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8997156\">",
"      - Oral cholecystography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58360586\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64850481\">",
"      Upper abdominal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64850435\">",
"      Other disorders with biliary-type pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58360623\">",
"      - Acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58365883\">",
"      - Choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58365923\">",
"      - Sphincter of Oddi dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58365735\">",
"      - Functional gallbladder disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22973321\">",
"      Category 1 patients (gallstones but no symptoms)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1067517491\">",
"      Category 2 patients (typical biliary symptoms and gallstones)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8997696\">",
"      - Pain management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H64850949\">",
"      Surgical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H64850928\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H64850996\">",
"      Complications and side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H64850956\">",
"      Alternatives to cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22973264\">",
"      Category 3 patients (gallstones but atypical symptoms)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8997815\">",
"      Category 4 patients (typical biliary symptoms but without gallstones on ultrasound)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2890985\">",
"      Patients with gallstone-related complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2891157\">",
"      Women with gallstones who are pregnant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/654\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/654|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?7/14/7407\" title=\"diagnostic image 1\">",
"      Calcified gallstones KUB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/14/42211\" title=\"diagnostic image 2\">",
"      Gallbladder polyp vs stone US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/14/2287\" title=\"diagnostic image 3\">",
"      Gallstones OCG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/654|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/35/28211\" title=\"picture 1\">",
"      Cholesterol crystals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/48/24325\" title=\"picture 2\">",
"      Bilirubinate crystals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/654|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/50/814\" title=\"table 1\">",
"      Prevalence of gallstones",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24790?source=related_link\">",
"      Acute cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/24/43399?source=related_link\">",
"      Adjuvant treatment for localized, potentially resectable gallbladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/55/43897?source=related_link\">",
"      Approach to the adult with chronic diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27720?source=related_link\">",
"      Approach to the patient with dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10374?source=related_link\">",
"      Approach to the patient with incidental gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40936?source=related_link\">",
"      Approach to the patient with suspected choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22455?source=related_link\">",
"      Clinical manifestations and diagnosis of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12874?source=related_link\">",
"      Clinical manifestations and diagnosis of sphincter of Oddi dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18792?source=related_link\">",
"      Complications of laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6408?source=related_link\">",
"      Dissolution therapy for the treatment of gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4489?source=related_link\">",
"      Epidemiology of and risk factors for gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14297?source=related_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/28/35272?source=related_link\">",
"      Functional dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8200?source=related_link\">",
"      Functional gallbladder disorder in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13209?source=related_link\">",
"      Gallbladder polyps and cholesterolosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28201?source=related_link\">",
"      Gallstone disease in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/62/26598?source=related_link\">",
"      Gallstone ileus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11338?source=related_link\">",
"      Laparoscopic cholecystectomy: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44565?source=related_link\">",
"      Mirizzi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36489?source=related_link\">",
"      Open cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/56/1923?source=related_link\">",
"      Patient information: Gallbladder removal (cholecystectomy) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/21/7507?source=related_link\">",
"      Patient information: Gallstones (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/29/8658?source=related_link\">",
"      Patient information: Gallstones (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14582?source=related_link\">",
"      Patient selection for the nonsurgical treatment of gallstone disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/12/22730?source=related_link\">",
"      Surgical management of gallbladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15511?source=related_link\">",
"      Treatment of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/35/7738?source=related_link\">",
"      Treatment of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33977?source=related_link\">",
"      Treatment of advanced, unresectable gallbladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/14/40169?source=related_link\">",
"      Treatment of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29126?source=related_link\">",
"      Treatment of sphincter of Oddi dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_62_31723="Lymphatic drainage of the head and neck";
var content_f30_62_31723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lymphatic drainage of the head and neck",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Lymph node group",
"      </td>",
"      <td class=\"subtitle1\">",
"       Anatomic areas drained",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Occipital",
"      </td>",
"      <td>",
"       Posterior scalp",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Postauricular",
"      </td>",
"      <td>",
"       Temporal and parietal scalp",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Preauricular",
"      </td>",
"      <td>",
"       Anterior and temporal scalp, midface, nose, anterior ear canal and pinna, lateral conjunctivae",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parotid",
"      </td>",
"      <td>",
"       Forehead and temporal scalp, midface, nose, external ear canal, middle ear, gums, parotid gland",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Submandibular (submaxillary)",
"      </td>",
"      <td>",
"       Cheek, nose, lips, anterior tongue, submandibular gland, buccal mucosa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Submental",
"      </td>",
"      <td>",
"       Central lower lip, floor of mouth, tongue",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Superficial cervical",
"      </td>",
"      <td>",
"       Skin, lower larynx, lower ear canal, parotid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Superior deep cervical",
"      </td>",
"      <td>",
"       Tonsil, adenoid, posterior scalp and neck, tongue, larynx, hypopharynx, thyroid, palate, nose, esophagus, paranasal sinuses, nasopharynx, other cervicofacial nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inferior deep cervical",
"      </td>",
"      <td>",
"       Dorsal scalp and neck, nasopharynx, superficial pectoral region of the arm, superior deep cervical",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_62_31723=[""].join("\n");
var outline_f30_62_31723=null;
var title_f30_62_31724="Palliative care assessment at admission criteria";
var content_f30_62_31724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for a palliative care assessment at the time of admission",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        A potentially life-limiting or life-threatening condition",
"        <em>",
"         and",
"        </em>",
"        ...",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Primary criteria*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The \"surprise question\":",
"        <em>",
"         You would not be surprised if the patient died within 12 months or before adulthood",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Frequent admissions (eg, more than one admission for same condition within several months)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Admission prompted by difficult-to-control physical or psychological symptoms (eg, moderate-to-severe symptom intensity for more than 24-48 hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complex care requirements (eg, functional dependency; complex home support for ventilator/antibiotics/feedings)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Decline in function, feeding intolerance, or unintended decline in weight (eg, failure to thrive)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Secondary criteria",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Admission from long-term care facility or medical foster home",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Elderly patient, cognitively impaired, with acute hip fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metastatic or locally advanced incurable cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic home oxygen use",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Out-of-hospital cardiac arrest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Current or past hospice program enrollee",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Limited social support (eg, family stress, chronic mental illness)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No history of completing an advance care planning discussion/document",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Primary criteria are global indicators that represent the minimum that hospitals should use to screen patients at risk for unmet palliative care needs.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Secondary criteria are more-specific indicators of a high likelihood of unmet palliative care needs and should be incorporated into a systems-based approach to patient identification if possible.",
"      <br>",
"       &Delta; These indicators are included based on a consensus panel opinion.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Weissman DE, Meier DE. Identifying patients in need of a palliative care assessment in the hospital setting. J Palliat Med 2011; 14:17. Copyright &copy; 2011 Mary Ann Liebert, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_62_31724=[""].join("\n");
var outline_f30_62_31724=null;
var title_f30_62_31725="Loop of Henle transport";
var content_f30_62_31725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ion transport in loop of Henle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 221px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the transport mechanisms in the thick ascending limb of the loop of Henle. The Na-K-ATPase pump in the basolateral (peritubular) membrane pumps sodium (Na) out of, and potassium (K) into, the cell. This creates a low intracellular Na concentration which drives many of the cell's reabsorptive processes. The entry of filtered sodium chloride (NaCl) into the cells is mediated by an electroneutral Na-K-2Cl (NKCC2) cotransporter in the apical (luminal) membrane. This is also called the furosemide sensitive cotransporter. The energy for this process is provided by the favorable inward electrochemical gradient for Na (the intracellular Na concentration is very low and the cell interior is electronegative). The inward movement of K and Cl occurs against their electrochemical gradients and is powered by the inward movement of Na into the cell. The reabsorbed Na which has entered the cell is pumped out by the Na-K-ATPase pump. The concentration of K in the filtrate and tubular fluid is much lower than that of Na and Cl and much of the reabsorbed K recycle back into the lumen through K channels (ROMK) in the apical membrane to allow continued NaCl reabsorption. This movement of cationic K into the lumen plus the flux of reabsorbed Cl out of the cell into the peritubular capillary (via Cl channels) causes the lumen to become more positively changed compared with the cell and peritubular space. This lumen electropositivity creates an electrical gradient that promotes the passive reabsorption of cations - Na, calcium (Ca), and magnesium (Mg) - via the paracellular pathway between the cells. The most important Cl channels in these cells are ClC-Kb. Also present but not as critical are the ClC-Ka channels. Each of these Cl channels requires interaction with a small protein called barttin to function normally. The single Cl channel shown in the figure represents both intact ClC-Ka and ClC-Kb channels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_62_31725=[""].join("\n");
var outline_f30_62_31725=null;
var title_f30_62_31726="Fetal lissencephaly";
var content_f30_62_31726=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fetal lissencephaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 244px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial magnetic resonance image of fetus at 29 weeks with diffusely smooth cortex, compatible with lissencephaly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_62_31726=[""].join("\n");
var outline_f30_62_31726=null;
var title_f30_62_31727="QT dispersion tangent method";
var content_f30_62_31727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Tangent method for measurement of QT interval",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 473px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The shape of the descending part of the T wave can effect the measurement of the QT interval when using the tangent method. The two hypothetical T waves have the same offset time (vertical solid line). However, the two T waves have a significantly different shape of the descending part; as a result, a tangent to the steepest point may significantly underestimate (top panel, red dash line) or overestimate the T wave offset (bottom panel, black dash line).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_62_31727=[""].join("\n");
var outline_f30_62_31727=null;
